Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1 by Rawal, Sumit
Utah State University 
DigitalCommons@USU 
All Graduate Theses and Dissertations Graduate Studies 
5-2010 
Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1 
Sumit Rawal 
Utah State University 
Follow this and additional works at: https://digitalcommons.usu.edu/etd 
 Part of the Veterinary Toxicology and Pharmacology Commons 
Recommended Citation 
Rawal, Sumit, "Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1" (2010). All Graduate 
Theses and Dissertations. 568. 
https://digitalcommons.usu.edu/etd/568 
This Dissertation is brought to you for free and open 
access by the Graduate Studies at 
DigitalCommons@USU. It has been accepted for 
inclusion in All Graduate Theses and Dissertations by an 
authorized administrator of DigitalCommons@USU. For 
more information, please contact 
digitalcommons@usu.edu. 
MECHANISMS OF THE EXTREME SENSITIVITY OF TURKEYS TO AFLATOXIN B1 
by 
Sumit Rawal 
A dissertation submitted in partial fulfillment 
of the requirements for the degree  
of 
DOCTOR OF PHILOSOPHY 
in 
Toxicology 
 
Approved:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UTAH STATE UNIVERSITY 
Logan, Utah 
2010
Dr. Roger A. Coulombe, Jr. 
Major Professor 
Dr. Steven D. Aust 
Committee Member 
Dr. Kenneth L. White 
ADVS Department Head 
Dr. Jeffery O. Hall 
Committee Member 
Dr. David D. Frame 
Committee Member 
Dr. Kevin D. Welch 
Committee Member 
Dr. Byron R. Burnham 
Dean of Graduate Studies 
 ii 
ABSTRACT 
Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1 
by 
Sumit Rawal, Doctor of Philosophy 
Utah State University, 2010 
Major Professor: Dr. Roger A. Coulombe, Jr. 
Department: Animal, Dairy and Veterinary Sciences  
The pathogenesis of hepatotoxic and hepatocarcinogenic actions of the 
mycotoxin aflatoxin B1 (AFB1) involves initial bioactivation by microsomal 
cytochrome P450s (P450) to a reactive and electrophilic intermediate, exo-
aflatoxin B1-8,9-epoxide (exo-AFBO). Poultry, especially turkeys, are extremely 
sensitive to AFB1, a condition associated with efficient epoxidation by P450s. The 
purpose of this research was to 1) discover and characterize the P450s in turkey 
liver responsible for AFB1 bioactivation, and 2) determine the relative importance 
of these P450s in turkey liver.   
Initial investigations led to the discovery of CYP1A5. We then identified 
CYP3A37, a human CYP3A4 homologue from turkey liver, which along with 
CYP1A5 plays an important role in the bioactivation of AFB1 to exo-AFBO. The E. 
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coli-expressed CYP3A37 possessed striking similarities to human CYP3A4, in 
terms of its catalytic activities and the kinetics of AFB1 oxidation. 
After the discovery of CYP3A37, further research evaluated its relative 
importance to CYP1A5, with respect to the epoxidation of AFB1, to determine 
which of the homologues bioactivated relatively low “real world” AFB1 
concentrations, reflective of the potential dietary exposure. Using  antibodies 
directed to both the enzymes as tools in immuno-inhibition experiments, we 
determined that CYP1A5 contributes to about 98% of the exo-AFBO formation at 
the low AFB1 concentrations (0.1 µM), which led us to conclude that CYP1A5 is 
likely the dominant homologue involved in the extreme sensitivity of the turkeys 
to AFB1.  CYP3A37 also efficiently epoxidated AFB1, but only at high 
concentrations of this mycotoxin, not likely to be achievable in turkey liver in 
vivo. Our research has helped shed light on the relative importance of CYP1A5 
and CYP3A37 in the bioactivation of AFB1 to the toxic exo-AFBO, and thus on the 
mechanisms of the extreme sensitivity of turkeys to AFB1. 
Given that AFB1 is a ubiquitous component of corn-based poultry feed 
and contamination is practically unavoidable, we conducted further studies 
evaluating the chemopreventive action of probiotic bacteria, Lactobacillus, on 
AFB1 toxicity in turkeys. Probiotic bacteria are known to bind AFB1, thus 
reducing its bioavailability. A mix of probiotic bacteria provided protection 
against key endpoints of aflatoxicosis, like AFB1-induced reduction in body and 
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liver weights. Our data demonstrate that Lactobacillus was protective against 
aflatoxicosis in turkeys, thus validating its use as a possible chemopreventive, 
thereby helping alleviate the significant annual losses to the poultry industry due 
to feed contamination by AFB1.    
(161 pages) 
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CHAPTER 1 
LITERATURE REVIEW1 
Aflatoxins  
Aflatoxins (AF) are the naturally occurring mycotoxins, produced as 
secondary metabolites by the fungus Aspergillus flavus, A. parasiticus, and A. 
nominus. The name “aflatoxin” is derived from the first letter in Aspergillus, and 
the first three letters in flavus (Schoental, 1967). Structurally, AFs are 
difurocoumarin derivatives that fluoresce under ultraviolet light. Depending 
upon color of the fluorescence, AFs are divided into aflatoxin B1 and B2 (AFB1, 
AFB2) for blue, and G1 and G2 (AFG1, AFG2) for green (Hartley et al., 1963; Dalvi, 
1986) (Figure 1.1). Aflatoxin M1 and M2 (AFM1, AFM2), known as milk-AFs, are 
the metabolites of AFB1 and AFB2, respectively (Carnaghan et al., 1963). 
Aflatoxins are the most intensively researched group of mycotoxins, because of 
their demonstrated toxic and carcinogenic effects in susceptible laboratory 
animals and livestock and their acute toxicological and chronic 
hepatocarcinogenic effects in humans. Of the known AFs, AFB1 is the most 
potent, and is a classified human carcinogen (Wogan et al., 1974; Wong and 
Hsieh, 1976; Bondy and Pestka, 2000).  
 
 
                                                 
1 Coauthored by Sumit Rawal, Ji Eun Kim and Roger A. Coulombe Jr. Portions of this review 
have been submitted for publication to the Research in Veterinary Sciences.  
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Toxicity of Aflatoxins 
AFB1 is toxic to a wide range of animal species. AFB1 is principally an 
hepatotoxin and hepatocarcinogen, but it causes a myriad of other effects either 
directly or indirectly associated with this toxicity: immunosuppresion, reduced 
growth rate, lowered milk and egg production, reduced reproductivity, reduced 
feed utilization, reduced feed efficiency, and anemia.  AFB1 has been shown to 
induce hepatocellular carcinoma in many species of animals including fish 
(rainbow trout, sockeye salmon, and guppy), poultry (turkeys, ducks, and geese), 
non-human primates (rhesus, cynomolgus, African green, and squirrel 
monkeys), and rodents (rats, mice, and tree shrews) (Wogan, 1992). A wide 
variation exists in the dose of AFs required to produce signs of liver cancer in 
different species. Fish and poultry, known to be extremely sensitive to AFB1, 
responded to doses as low as 15-30 ppb. Rats responded at concentrations of 15-
1000 ppb, whereas mice showed no effects to concentrations as high as 150, 000 
ppb (Wogan, 1992). In rainbow trout, dietary AFB1 concentrations of 20 ppb 
resulted in a liver tumor incidence of 62% (Bailey et al., 1988).   
Primates showed a wide variability in AFB1 susceptibility to hepatic 
tumors (Adamson, 1989). While squirrel monkeys developed liver cancer when 
fed AFB1 at 2000 ppb for 13 months, much higher doses were required over a 
longer period of time to induce low incidence of liver carcinoma in rhesus, 
cynomolgus and African green monkeys (99 to 1,225 mg/animal administered 
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p.o. over periods of 48 to 179 months). However, AFB1 induced tumors in 
extraheptic tissues in the latter species. 
Species susceptibility to various acute toxic manifestations, as measured 
by TD50, is likewise variable (Gold et al., 1984; Wogan, 1992). While Fisher rats 
appear to be extremely sensitive (TD50: 1.3 mg/kg/body weight/day), Swiss 
mice are highly resistant (TD50: >5300 mg/kg/body weight/day). Rhesus and 
cynomolgus monkeys dosed for an average of 3.3 and 14 years, respectively, 
yielded a TD50 value of 156 and 848 mg/kg/body weight/day, respectively.   
Acute aflatoxicosis in humans is manifested by vomiting, abdominal pain, 
pulmonary edema, coma, convulsions, and death with cerebral edema and fatty 
involvement of the liver, kidney, and heart (Strosnider et al., 2006). The 
occurrence of acute aflatoxicosis was evidenced by the severe outbreak in Kenya 
in 2004 (Probst et al., 2007). Epidemiological studies have consistently 
demonstrated that AFB1 is a liver carcinogen in humans (Van Rensburg et al., 
1985; Groopman et al., 1988). Studies conducted in Swaziland and Guangxi, 
China have linked AFB1 exposure to development of liver cancer in humans 
(Peers et al., 1987; Yeh et al., 1989).  The International Agency for Research on 
Cancer has concluded that there is sufficient evidence for the carcinogenicity of 
AFB1 in humans and hence placed this mycotoxin under group I (confirmed 
carcinogen).  
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Aflatoxin B1 is a “pro-carcinogen” in that enzymatic bioactivation is a 
prerequisite for carcinogenic (and toxic) activity (Garner et al., 1972). 
Accordingly, elucidation of the mechanisms of AFB1 metabolism has been the 
focus of intense research over the years. AFB1 is metabolized by hepatic 
microsomal cytochrome P450s (P450) to the reactive, electrophilic exo-AFB1-8,9- 
epoxide (AFBO) which binds to DNA and other critical cellular macromolecules 
(Ball and Coulombe, 1991; Wogan, 1992; Coulombe, 1993; Gallagher et al., 1996; 
Guengerich et al., 1996a).  The AFBO is highly unstable, and it reacts with DNA 
to form N7 guanine adducts by intercalation of AFBO between base pairs (Iyer et 
al., 1994).  
In humans and most animals, the principal route of detoxification appears 
to be through conjugation with endogenous glutathione (GSH), a reaction 
catalyzed by glutathione-S-transferases (GSTs). There exists substantial amount 
of evidence that the conjugation of the epoxide by GSH is a major factor in 
determining the susceptibility of a species to AFB1 (Hayes et al., 1991). For 
example, quail and rat are much more sensitive to AFB1 toxicity and 
carcinogenicity than the more resistant mouse, yet all these animals exhibit high 
rates of P450-mediated AFBO formation. The relatively high rate of GSH 
conjugation by a constitutive alpha class GSTA3-3 appears to be the critical 
resistance factor in mice (Hayes et al., 1992).  Resistance in the rat to AFB1-
induced hepatocarcinogenesis can by enhanced by induction of a similar GST in 
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liver which is constitutively expressed at low levels (Stresser et al., 1994).  In non-
human primates, evidence has been presented that GSTs in the mu-class, rather 
than alpha, are most efficient in conjugation of AFBO (Wang et al., 2000).  The 
lack of a functional GST with affinity toward AFBO appears to be a major reason 
that poultry are extremely susceptible to AFB1 (Klein et al., 2000).  
There are a number of urinary and serum biomarkers that have been 
validated to accurately predict AFB1 cancer risk in humans. Biomarkers for AF 
exposure include dose-dependent urinary excretion of aflatoxin-N7-guanine and 
AFM1 (Gan et al., 1988; Groopman et al., 1992; Groopman and Kensler, 1999). 
Urinary excretion of mercapturic acid (AFB-NAC), a product of GSH adduction 
of AFB1 mediated by GSTs, has also been used in field studies (Wang et al., 1999). 
Serum AF-albumin adducts, which are positively associated with hepatocellular 
carcinoma in humans (Wang et al., 1996) has found wide use in epidemiologic 
studies (Wild and Turner, 2001). Analysis of serum adducts indicates a positive 
correlation between dietary AFB1 exposure and serum AFB-albumin adducts 
(Gan et al., 1988; Wild et al., 1992).  
 
Aflatoxin B1 toxicity in Poultry   
Poultry, especially turkeys, are extremely sensitive to the toxic effects of 
AFB1 (Carnaghan et al., 1966; Arafa et al., 1981; Giambrone et al., 1985; Huff et al., 
1986; Kubena et al., 1995; Klein et al., 2000). Extreme sensitivity of turkeys to AFB1 
was first and graphically demonstrated by association with „Turkey X Disease‟ 
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which caused widespread deaths of turkeys and other poultry throughout 
Europe in the 1960s (Stevens et al., 1960). The disease was shown to be caused by 
AFB1 contaminated feed (Smith, 1960). It was later reported that the 
contamination with AFs came from Brazilian peanut meal (Blount, 1961). Among 
different poultry species, turkeys were shown to be the most susceptible to AFs, 
quail are intermediate, while chickens are considered relatively resistant (Arafa 
et al., 1981; Lozano and Diaz, 2006). Although direct comparisons have not been 
conducted, wild turkeys appear to be less susceptible to AFB1 than their 
commercial counterparts (Quist et al., 2000).  
Dietary aflatoxins at 0.7 ppm reduced the growth rate of turkey poults, 
but had no effect in quails and chickens (Arafa et al., 1981). A diet containing 400 
ppm AFB1 severely affected body and relative liver weights in turkeys, while 
chickens showed no effect at this dietary concentration (Leeson et al., 1995). A 
study examining the effects of AFB1 on the development of liver lesions in 
poults, indicated ducks as more susceptible than turkeys and chickens (Coker, 
1979). In that study, ducks developed hepatic lesions by dietary exposure to 30 
ppb, turkeys at 300 ppb, while chickens responded to 500 ppb. Another study 
evaluated the effects of AFB1 on the development of cytopathology in the 
tracheal culture in day-old turkeys, Japanese quails, chicken and ducks (Colwell 
et al., 1973). While cultures derived from ducks developed pathology at 6 ppb of 
AFB1, the concentrations needed for equivalent pathology were as high as 100 
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ppb for those from chickens. Tracheal cultures from turkeys and quails 
responded to 28 and 47 ppb of AFB1, respectively.  
 
Economic Losses to the Poultry Industry due to Aflatoxins  
Turkeys are an important international food commodity. The United 
States accounts for roughly one-half of the world‟s turkey production at 
approximately 7.30 billion pounds, live weight, with an estimated value of nearly 
US $ 3 billion (National Agricultural Statistics Service, USDA).  The per capita 
consumption of turkeys in the United States is approximately 18 pounds, and 
turkeys are now the 4th major food and protein source, behind chicken, beef and 
pork (National Turkey Federation).    
Aflatoxins result in economic losses to the poultry industry from 
reductions in growth rate, hatchability, feed efficiency and immunity towards 
diseases (Richard et al., 1986; Coulombe, 1993). According to a report by the 
Council for Agricultural Science and Technology, losses due to AFs to the US 
poultry industry exceeded $143 million annually (CAST, 1989). A recent study 
reported annual crop losses of $932 million due to mycotoxin contamination and 
additional losses of $466 million in efforts to prevent or reduce contamination 
(CAST, 2003).  Although AFs are found in several feed ingredients, corn, peanut 
meal, cottonseed meal, and sorghum appear to be at greatest risk for introducing 
AFs in turkey diets (Pons and Goldblatt, 1965; Brekke et al., 1977; Winn and Lane, 
1978; Hill et al., 1983).  Crops contaminated with AFs are a worldwide problem 
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and approximately 25% of world‟s food supply is contaminated with mycotoxins 
(CAST, 1989). Conditions that favor contamination by mycotoxins include 
excessive moisture both in field and post harvest storage, high humidity, 
temperature extremes, drought stress and insect damage to crops (Coulombe, 
1993). Aflatoxins are deleterious to poultry and their contamination in feed is 
practically unavoidable (Coulombe et al., 2005). The United States Food and Drug 
Administration regulates the amount of AFB1 allowed in poultry feed. The 
current action level for corn and peanut products is 100 ppb and for cottonseed 
meal 300 ppb. 
  Consumption of AFB1 contaminated feed results in poor performance, 
decreased body and organ weights, immunosuppression, morbidity, and 
mortality in turkeys (Kubena et al., 1990, 1991; Coulombe, 1993). Aflatoxins 
significantly affect feed consumption, total plasmatic proteins and cholesterol 
amounts of turkeys (Rauber et al., 2007). Furthermore, AFs lead to irreversible 
liver damage as indicated by decreased liver-to-body weight ratios, liver enzyme 
alterations, altered blood coagulation patterns, and histologic changes like 
hepatocellular necrosis and biliary hyperplasia in turkeys (Quist et al., 2000; Klein 
et al., 2002b). Dietary exposure of broiler hens to AF (10 ppm) resulted in 
embryonic mortality and lowered the immunity in the progeny chicks (Qureshi 
et al., 1998). Embryonic exposure with AFs resulted in long-term depression of 
the immune function in chicks (Neldon-Ortiz and Qureshi, 1992). As in other 
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species, the liver is the most severely affected organ in poultry, primary 
consequences being hepatic necrosis and neoplasias (Klein et al., 2000).  
 
AFB1 Metabolism in Poultry: Role of Cytochrome P450s  
Cytochrome P450s are mixed-function oxidases that catalyze the 
biotransformation of a wide variety of xenobiotics. They are a superfamily of 
hemoproteins that aid in the oxidation of various substrates such as steroids, 
eicosanoids, pharmaceuticals, pesticides, pollutants, and carcinogens (Parikh et 
al., 1997). Cytochrome P450s play an important role in the formation of 
carcinogenic and mutagenic electrophilic intermediates from naturally occurring 
dietary compounds (Guengerich et al., 1996a). As mentioned previously, AFB1 is 
not toxic per se, but requires metabolic conversion to the reactive and 
electrophilic exo-AFBO by P450s to exert its toxic effects (Ball and Coulombe, 
1991; Coulombe, 1993; Gallagher et al., 1996; Guengerich et al., 1996a). This 
metabolite can induce mutations by alkylating DNA, principally at the N7 
position of guanine forming the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 (Lin 
et al., 1977). In addition AFBO can bind to proteins and other critical cellular 
nucleophiles.  
Turkey liver P450s are especially efficient toward AFB1 bioactivation 
compared to other poultry species thus far examined. Turkey liver microsomes 
bioactivated AFs 1.8 and 3.5 times more than liver microsomes from quail and 
chicken, respectively (Lozano and Diaz, 2006). When comparing livers obtained 
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from 9, 45 and 61 day old turkeys, microsomes from younger were more active 
toward AFB1 bioactivation than that from older birds (Klein et al., 2002a). 
 In turkey liver, AFB1 metabolism is mediated by homologues to human 
CYP1A2 and CYP3A4 (Klein et al., 2000; Klein et al., 2003; Yip and Coulombe, 
2006). Initial studies reported that concentrations of AFB1 which are likely to be 
achieved in the liver following ingestion of “real-world” concentrations of AFB1 
are bioactivated to AFBO primarily by CYP1A2, whereas much higher 
concentrations are catalyzed by CYP3A4 (Gallagher et al., 1996; Kelly et al., 1997; 
Van Vleet et al., 2002). CYP1A homologues also metabolize AFB1 to produce the 
detoxified metabolite AFM1, whereas CYP3A enzymes produce another 
detoxified metabolite, aflatoxin Q1 (AFQ1) (Campbell and Hayes, 1976; 
Guengerich et al., 1996a) (Figure 1.2). 
Although both CYP1A and 3A isoforms oxidize AFB1, there are conflicting 
reports on their relative importance (Shimada and Guengerich, 1989; Ramsdell 
and Eaton, 1990; Gallagher et al., 1994, 1996). A recent study demonstrated a 
dominant contribution of CYP3A4 homologues in AFBO production.  Aflatoxin 
B1 metabolism studies in human liver microsomal preparations indicate a 
predominant role for CYP3A4 and that its expression level was an important 
determinant of the AFB1 disposition in human liver (Kamdem et al., 2006).  
Specific CYP3A4 inhibitors like troleandomycin have been shown to inhibit 
AFBO production (Gallagher et al., 1994), while inducers of CYP3A4 activity such 
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as 3-methylcholanthrene and rifampicin, increase AFB1 metabolism in cultured 
human hepatocytes (Langouet et al., 1995). 
Although mammalian P450s are well described, limited information is 
available on P450s in poultry, especially in the context of AFB1 metabolism. 
Chicken P450s, CYP1A5 (Gilday et al., 1996) and CYP3A37 (Ourlin et al., 2000) 
have been described. This laboratory recently cloned, expressed and 
characterized CYP1A5 from turkey liver, the first functional protein amplified 
from turkeys (Yip and Coulombe, 2006). CYP1A5 is predicted to be 528 amino 
acids with 94.7% sequence identity to chicken CYP1A5. Like its human 
homologue, the E. coli-expressed CYP1A5 efficiently bioactivated AFB1 to AFBO, 
and in addition, produced AFM1. Recombinant P450 heterologously expressed in 
E. coli proved to be very useful for the studies of turkey CYP1A5. After the 
discovery of a CYP1A homologue, the next task was to identify the existence of 
possible CYP3A4 homologue involved in AFB1 oxidation and determine its 
relative importance compared to CYP1A5.   
An important detoxification mechanism for AFB1 is the GST catalyzed 
conjugation of AFBO with GSH (Hayes et al., 1991). Detoxification mediated by 
GSTs plays a major role in species susceptibility to AFs (Coulombe, 1993). 
Commercial turkeys appear to be deficient in this detoxification mechanism 
which is an important reason for their extreme sensitivity to AFB1 (Klein et al., 
2000).  Therefore, the extreme sensitivity of turkeys to AFB1, is, in part, due to a 
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combination of efficient oxidation by P450s and deficient detoxification by GSTs 
(Klein et al., 2000; Yip and Coulombe, 2006) (Figure 1.2).  
 
Recombinant P450 systems to study  
AFB1 Biotransformation   
The study of P450s has been greatly facilitated by their expression in 
heterologous systems, especially E. coli. The past two or three decades have seen 
a tremendous growth in the engineering of recombinant P450s to study their 
xenobiotic metabolism activity. Several expression hosts have been developed: 
yeast (Murakami et al., 1987), mammalian cells (Crespi et al., 1991), 
baculovirus/insect cells (Buters et al., 1994) and bacteria (E. coli). Escherichia coli 
became a popular choice for the heterologous expression of P450s. The technique 
started with the expression of P450 in E. coli through N-terminal modifications 
(Barnes et al., 1991). Although this technique produced significant expression 
levels for P450s (16 mg of spectrally detectable bovine P45017α per liter of 
culture) (Barnes et al., 1991), the study of drug metabolism was often limited due 
to the lack of endogenous electron donors NADPH-P450 reductase (NPR). While 
E. coli contains flavoproteins which could couple to some degree with P450 
(Jenkins and Waterman, 1994), the rate of catalysis was often slow. To overcome 
this limitation P450s were co-expressed with NPR in E. coli (through bicistronic 
expression or the use of fusion proteins) producing independent functionally 
relevant P450 monooxygenase systems (Dong and Porter, 1996; Parikh et al., 
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1997). Thus, several P450s have been co-expressed with their partner reductase 
successfully in E. coli (Parikh et al., 1997).  
N-terminal modifications of native cDNAs: P450s were difficult to 
express in their native form due to their hydrophobicity. Generally P450s require 
alterations in the hydrophobic N-terminal nucleotide sequence (5‟ end) to 
facilitate translation by E. coli (Barnes et al., 1991). This was due to the fact that N-
terminal sequences serves as signal for membrane anchoring but plays no role in 
the catalytic activity of P450 or its interactions with the coupling enzyme. 
Initially, Barnes and coworkers (Barnes et al., 1991) were successful in the 
expression of bovine P45017α1 by modifying N-terminal sequences. Specifically, 
the second codon was changed to GCT (Ala) which encodes the LacZ gene, and 
codons 4 and 5 were changed to increase the AT content by silent mutagenesis. 
This reduced the free energy for base pairing and inhibited the formation of 
secondary structures in the mRNA which could inhibit translation (Guengerich 
et al., 1996a). This pioneering work led to abundant (16 mg of spectrally 
detectable P450 per liter of culture) bovine P45017α1 expression levels in E. coli 
(Barnes et al., 1991). Subsequently, several other P450s were expressed by 
modifying and/or truncating the N-terminal sequences utilizing the above 
mentioned strategy or using a different one (Fisher et al., 1992a, 1992b; Guo et al., 
1994; Sandhu et al., 1994). The majority of the methods for heterologously 
expressed P450s follow a general procedure involving N-terminal sequence 
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alterations. Native P450s usually were expressed in insignificant amounts 
(Barnes et al., 1991; Dong and Porter, 1996). Another strategy of N-terminal 
alteration is the fusion of a bacterial ompA (outer membrane protein A) leader 
sequence (21 amino acids) and two additional spacer amino acids (Ala-Pro) to 
P450 cDNAs in-frame with P450 initiation codon. This (Pritchard et al., 1997) 
approach does not involve changes in the native P450 sequence and the leader 
sequence is removed during bacterial synthesis releasing native P450.  
Another 5‟ end modification is the introduction of a restriction site for 
cloning in a vector {usually NdeI for cloning in pCW vector (Barnes et al., 1991)}. 
Modifications at the 3‟ end usually involve introduction of 4-6 hisitidine residues 
to facilitate purification of P450s by affinity Ni2+-NTA chromatography (Crowe et 
al., 1994) and also to include a restriction site.  
N-terminal modifications have been shown to not alter the catalytic 
activities of the P450s, because of their prominent role in the membrane 
localization (Barnes et al., 1991). These peptides do not participate in formation of 
the active sites, which interact with the substrates. Loss of the catalytic activities 
of the heterologously expressed P450s were mostly associated with the lack of 
endogenous NPR and the necessary transfer of the electrons. Bicistronic vectors, 
discussed below, overcame this difficulty by producing independent functionally 
relevant P450s.  
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Expression Vector: The pCW vector (Figure 1.3) developed in the 
laboratory of Prof. F. W. Dahlquist has been used extensively to express modified 
P450 cDNAs  (Gegner and Dahlquist, 1991). pCW functions by two tac promoter 
(inducible by isopropyl-thiogalactoisde:IPTG) cassettes upstream of an NdeI 
(CATATG) restriction enzyme cloning site coincident with the initiation ATG 
codon. This vector contains a strong transcription termination mechanism and a 
phage M13 origin of DNA replication. Transcription prior to the addition of 
inducing agents is inhibited by LacI gene encoding a lac repressor molecule. 
pCW can also function as a bicistronic vector to co-express P450 and NADPH-
P450 reductase (Parikh et al., 1997). Bicistronic operons consisting of P450 cDNA 
as the first cistron followed by NADPH-P450 reductase cDNA as the second 
cistron can be ligated into the pCW vector multicloning site (Parikh et al., 1997). 
The use of special restriction sites facilitates the process of subcloning in the 
pCW vector. This bicistronic vector proved to be extremely useful for studying 
the biotransformation of xenobiotics with P450s since it represented the fully 
functional P450 monooxygenase system in whole cells or isolated membranes. 
The presence of the reductase ensured that the electron transfer to P450 is not 
rate- limiting as it was previously for just P450 expressed vectors. Dong and 
Porter (1996) also produced a bicistronic vector pJL2E1/OR for expressing 
P4502E1 with rat NPR. They employed a different technique which involved no 
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modification of the N-terminal sequence. However, P450 yield was not 
significant which limited the catalytic studies.  
Another approach of producing a fully functional P450 monooxygenase 
system comes with the co-expression of P450 with reductase as a fusion protein 
(Fisher et al., 1992b; Shet et al., 1993) like the one present in naturally occurring 
P450 BM3 (from Bacillus megaterium). The rationale for this approach is the 
mutagenesis enabled alteration of C-terminal of P450 and N-terminal of 
reductase to allow the fusion of the two sequences with a dipeptide linker, Ser-
Thr. These fusion proteins exhibited catalytic activity only in presence of 
phospholipids and no apparent improvement in the activity was seen with their 
use.  
Because of its advantages mentioned above we chose bicistronic pCW 
based vectors for expression in E. coli. Vectors other than pCW are also used for 
P450 expressions, including pBSIISK (Stratagene), pSE420 (Invitrogen), pSE380 
(Invitrogen), etc.  
Expression in E. coli:  Several strains of E. coli are commercially available: 
such as JM109 (Invitrogen, Stratagene), XL 1-Blue (Stratagene), TOPP3 
(Invitrogen, Stratagene), and DH5α (Invitrogen). Co-expression of P450 and 
reductase in a bicistronic vector appears to be most efficient in DH5α (Parikh et 
al., 1997; Yip and Coulombe, 2006). Expression constructs are transformed in 
competent E. coli cells and streaked on Luria-Bertani (LB) agar/ampicillin plates, 
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and allowed to grow at 37oC overnight. Starter culture consists of LB-ampicillin 
medium inoculated with a single colony, and grown at 37oC with shaking. 
Terrific broth (TB) medium has been extensively used for growing bacterial 
cultures containing recombinant plasmids. It is usually supplemented with 
thiamine, trace elements, ampicillin (50-100 μg/ml), heme precursor δ-
aminolevulinic acid (δ- LA) (0.5 mM), and an inducer of transcription IPTG 
(1mM). Cells are grown usually for 28-48 hr at 28-32oC. While some studies 
indicate addition of IPTG at the start of TB culture (Guengerich et al., 1996b), 
others have chosen to add IPTG after the cells in main culture in TB medium 
have grown to an OD600 of 0.3-0.5 at 37oC (Jenkins et al., 1998; Yip and Coulombe, 
2006). Addition of δ-ALA seems to increase P450 expression in some cases 
(Gillam et al., 1995). Expressed P450s can be quantified in whole cells by CO 
difference spectra, which is absorbance difference at 450 nm between reduced 
hemoprotein (Fe2+) and the reduced hemoprotein bound to CO (Fe2+.CO) 
(Omura and Sato, 1964).  
Purification of P450 from membranes: Guengerich and coworkers 
(Guengerich et al., 1996b), described a detailed method for the purification of 
recombinant P450s expressed in E. coli. Bacterial cells in culture are harvested 
and treated with lysozyme to prepare spheroplasts. Spheroplasts lysed in the 
presence of protease inhibitors like phenylmethylsulfonyl fluoride (PMSF) gives 
 18 
rise to a lysate which is subjected to ultra centrifugation for 60 min at 4oC to 
separate the membrane and cytosolic fraction.  
Purification of P450 from the E. coli membranes makes use of the oligo-His 
region at the C-terminal end Ni2+-NTA affinity chromatography (Crowe et al., 
1994). Membranes were first solubilized with surfactants/detergents like sodium 
cholate, Triton X-114, CHAPS etc., before being subjected to chromatography (via 
a combination of ion-exchange and affinity or just affinity) to purify enzyme 
expressed in E. coli membranes (Hosea et al., 2000).  
 
Chemoprevention of Aflatoxicosis in Poultry    
The National Cancer Institute defines chemoprevention as the use of 
naturally-occurring or synthetic agents to reduce the risk of, or delay the 
development or recurrence of, cancer. Given that AFB1 contamination in the feed 
is nearly universal, and therefore practically unavoidable (Coulombe et al., 2005), 
chemoprevention strategies aimed at reducing AFB1 toxicity in poultry and in 
other animals have been the subject of numerous studies (Klein et al., 2002b, 2003; 
Guarisco et al., 2008a, 2008b).  Several chemopreventives have been evaluated in 
poultry for reducing symptoms of aflatoxicosis. Indeed, because of their 
sensitivity, poultry have been used as models in the search for novel AFB1 
chemopreventives. 
Clay-based inorganic adsorbents, which prevent absorption of AFB1 into 
the general circulation, hence reducing bioavailability, have been extensively 
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studied.  In broiler chicks, adsorbents like calcium montmorillonite clay (0.5, 0.25, 
and 0.125% in diet), and Zeolites (1% in diet), which bind to AFB1 preventing 
their absorption, have been shown to be protective against high AFB1 exposure 
of 5 and 2.5 ppm, respectively (Miazzo et al., 2000; Pimpukdee et al., 2004). 
Hydrated sodium calcium aluminosilicate (HSCAS), fed at dietary 
concentrations ranging from 0.25-1%, has been shown to diminish the deleterious 
effects of AF (up to 5 ppm in diet) in broiler chicks (Kubena et al., 1993, 1998; 
Ledoux et al., 1999).  Another adsorbent, clinoptilolite (15 g/kg), provided 
moderate amelioration in AF associated liver toxicity (hydropic degeneration 
and biliary hyperplasia) in broiler chicks (Ortatatli et al., 2005). 
Detoxification of contaminated feed with microorganisms has been tested 
as a strategy to reduce the AF-associated toxicity. In a recent study, the 
detoxification potential of Nocardia corynebacteroides (NC), as a feed additive, was 
evaluated in day-old Ross 308 chicks; NC significantly reduced the AF-associated 
lesion severity in liver, duodenum and kidneys (Tejada-Castaneda et al., 2008). 
Another report indicated the protective effect of Silymarin, a potent 
hepatoprotective in humans, against aflatoxicosis in broiler chicks. Although the 
mechanism of protection from Silymarin is uncertain, reports suggest that it acts 
as an antioxidant and cell membrane stabilizer and promotes the cellular 
synthesis of macromolecules (Tedesco et al., 2004).  Dietary administration of a 
Silymarin-phospholipid complex (600 mg/kg of body weight) resulted in 
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significant improvement in weight gain and feed intake in broiler chicks fed 
AFB1 (0.8 ppm) in the diet (Tedesco et al., 2004). In addition, vitamin D and water 
soluble vitamins like A, E and K are shown to be protective against aflatoxicosis 
in quail chicks (Wilson et al., 1975, 1978). 
The food antioxidant butylated hydroxytolouene (BHT) has been shown 
in numerous studies to reduce symptoms of aflatoxicosis in mammalian and 
avian models. In rodent models, BHT has been shown to reduce the development 
of cancer by either induction of phase II enzymes like GSTs or inhibition of phase 
I enzymes like P450s (Hocman, 1988; Singletary, 1990).  Weight loss in chickens 
due to AFB1 (3000 ppb in diet) was shown to be dramatically improved by 
dietary BHT at a concentration of 0.39% (Larsen et al., 1985). Likewise, dietary 
BHT protects against aflatoxicosis in turkeys. A diet containing 4000 ppm BHT 
provided significant protection against AFB1-induced weight loss, hepatocellular 
necrosis, biliary hyperplasia and changes in serum enzymes indicative of 
hepatotoxicity, in turkeys (Klein et al., 2002b).  Mechanism studies later revealed 
that while BHT induced GST expression and activity, none of the GSTs so 
induced had affinity toward AFBO (Klein et al., 2003).   The protective properties 
of BHT appeared to be due to an inhibitory effect on the activity of P450 1A1 and 
1A2, suggesting reduced bioactivation of AFB1 to the AFBO (Klein et al., 2003). 
Further studies revealed that dietary BHT reduced AFBO formation, as well as 
other CYP1A5-mediated activities (Guarisco et al., 2008b). Importantly, BHT 
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inhibited conversion of AFB1 to AFBO, exhibiting Michaelis-Menton competitive 
inhibition kinetics (Ki=0.81 µM). Inhibition of AFBO formation was found in 
microsomes prepared from the birds fed 4000 ppm BHT, as well as in 
microsomes treated with BHT in vitro. Moreover, BHT (4000 ppm in the diet for 
10 days) caused significant reductions in AFB1 bioavailability, AFB1–DNA 
adduct formation in the liver, and AFB1 residues in tissues in turkeys (Guarisco 
et al., 2008a). 
A number of recent studies have demonstrated that probiotic bacteria 
offers protection against AFB1 in humans and animals.  The mechanism of 
protection is through binding of AFB1 by cell wall constituents of probiotic 
bacteria, such as Lactobacillus rhamnosus. Because of its use in various dairy 
products including yogurt, L. rhamnosus is considered a safe and effective 
chemopreventive. Lactobacillus rhamnosus strain GG and LC-705 were found to be 
most efficient in binding a range of mycotoxins including AF (El-Nezami et al., 
1998, 2002a, 2002b; Haskard et al., 2001; Peltonen et al., 2001). In addition, L. 
rhamnosus reduced AFB1 transport, metabolism, and toxicity in cultured Caco-2 
cells (Gratz et al., 2007). Furthermore, L. rhamnosus reduced AFB1 bioavailability 
in rats, thereby decreasing its toxicity (Gratz et al., 2006). Thus, there exists 
substantial evidence of the protective role of probiotics in preventing 
aflatoxicosis. Given the potential of probiotic bacteria in binding AFB1, the 
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present study aims to evaluate their chemopreventive action on AFB1 toxicity in 
turkeys, a species extremely susceptible to aflatoxicosis.  
 
Research Goals  
Given the importance of P450s in the metabolic activation of AFB1, leading 
to its toxicity, the aim of this research was to discover and characterize the P450 
homologues involved in the bioactivation of AFB1 in turkey liver and to 
determine their relative importance. Given that AFB1 is nearly ubiquitous in 
corn-based poultry feed and contamination is practically unavoidable, another 
goal was to evaluate the chemopreventive action of o probiotic bacteria, 
Lactobacillus, on AFB1 toxicity in turkeys. 
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Figure 1.1. Chemical structures of major aflatoxins 
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Figure 1.2. Metabolism of AFB1: role of P450s and GSTs. The extreme sensitivity 
of turkeys to AFB1 is associated with efficient AFB1 epoxidation catalyzed by 
CYP1A5 and CYP3A37 coupled with deficient GST detoxification.  The 
hydroxylated metabolites, AFM1 and AFQ1 are formed by CYP1A5 and 
CYP3A37, respectively.  
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Figure 1.3. A pCW based bicistronic vector for co-expression of P450 with human 
NADPH P450 reductase (adapted from Gillam and Guengerich, 2001). The P450 
and reducatse cDNAs are inserted in series in a single expression cassette under 
the control of tandem tac promoters. Each cDNA is optimally positioned with a 
ribosomal binding site. The operons are driven by IPTG inducible double tac 
promoters placed upstream of first cistron. 
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CHAPTER 2 
STRUCTURE, GENETIC MAPPING, AND FUNCTION OF THE 
CYTOCHROME P450 3A37 GENE IN THE TURKEY (MELEAGRIS 
GALLOPAVO)2  
  
Abstract 
Cytochromes P450 (P450 for protein; CYP for gene) are a superfamily of 
membrane-bound hemoproteins that oxidize a large number of endogenous and 
exogenous compounds.   Through oxidation reactions, these enzymes are often 
responsible for the toxic and carcinogenic effects of natural food-borne toxicants, 
such as the mycotoxin aflatoxin B1 (AFB1).  Previous studies in our laboratory 
have shown that the extreme sensitivity of turkeys to AFB1 is in part explained 
by efficient hepatic P450-mediated epoxidation to the toxic and reactive 
metabolite, exo-AFB1-8,9-epoxide (AFBO).  Using 3‟-5‟-rapid amplification of 
cDNA ends (RACE), we amplified CYP3A37 from turkey liver RNA, the E. coli-
expressed protein which efficiently epoxidates AFB1.  Turkey CYP3A37 has an 
ORF of 1512 bp, and the protein is predicted to be 504 amino acids with 97% 
homology to chicken CYP3A37.  The turkey gene is organized into 13 exons and 
12 introns.  A single nucleotide polymorphism in the 11th intron was used to 
assign CYP3A37 to turkey linkage group 10 (corresponding to chicken 
                                                 
2 Coauthored by Sumit Rawal, Kristelle M. Mendoza, Kent M. Reed, and Roger A. Coulombe Jr. 
(2009) Cytogenetics and Genome Research 125: 67-73. © 2010 S. Karger AG, Basel. Reprinted with 
permission. 
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chromosome 14, GGA14).  Because of the important role of P450s in the extreme 
sensitivity of turkeys to the toxic effects of AFB1, this study will contribute to the 
identifying allelic variants of this important gene in poultry.  
 
Introduction  
Cytochromes P450 (“P450” for protein; CYP for gene) are a superfamily of 
hemoproteins that catalyze a large number of endogenous and exogenous 
compounds.  Of particular relevance to toxicology, P450s are known to oxidize 
hundreds of environmental chemicals to form reactive intermediates that are 
toxic and carcinogenic. One good example is the carcinogenic mycotoxin 
aflatoxin B1 that requires P450 oxidation at the 8,9 vinyl bond to produce the 
reactive and electrophilic exo-AFB1-8,9-epoxide (AFBO) to exert its toxic and 
carcinogenic properties (Van Vleet et al., 2002).  The critical lesion responsible for 
these properties is the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 adduct 
formed when the AFBO reacts with DNA (Iyer et al., 1994).  Much of the 
observed interspecies variability in susceptibility to AFB1 can be attributed to 
differences in AFB1 biotransformation (Eaton and Gallagher, 1994).   Aflatoxin B1 
is a recognized hepatocarcinogen and hepatotoxicant in humans and animals.  In 
humans, AFB1 is epoxidated principally by P4503A4 (the major P450 form in the 
liver), and to a lesser extent by P4501A2 (Kamdem et al., 2006).   
Turkeys are extremely sensitive to the toxic effects of AFB1 (Coulombe, 
1993; Giambrone et al., 1985), a condition we have previously shown to be 
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associated with efficient hepatic P450-mediated epoxidation. As in humans, AFB1 
is epoxidated to AFBO by both P450 1A and 3A homologues in turkey liver 
(Klein et al., 2000).  Aflatoxin B1 was discovered in the early 1960s as the 
etiological agent of “Turkey X” disease, responsible for the widespread deaths of 
turkeys and other poultry throughout Europe due to contaminated Brazilian 
peanut meal in feed (Asao et al., 1965).  We recently cloned and expressed 
P4501A5 from turkey liver, which like the human homologue, P4501A2, 
efficiently epoxidates AFB1 to produce the exo-AFBO as well as the detoxified 
metabolite aflatoxin M1  (Yip and Coulombe, 2006).  Because of the importance of 
P4503A4 in the toxicity of AFB1 in humans and animals, we sought to 
characterize the homologue of this enzyme in turkey liver.  Here, we report the 
cloning, genetic mapping and biological activity of P4503A37 from turkey.  Like 
P4503A4, the human homologue, the expressed protein from CYP3A37 
efficiently epoxidates AFB1 to form exo-AFBO.  
 
Materials and Methods 
Gene amplification, sequencing, and genetic mapping.  Messenger 
RNAs from one-day-old male turkeys were amplified by 3‟-5‟ RACE as described 
(Yip and Coulombe, 2006).  Primers used in 3‟-RACE were designed based on 
ClustalW (www.ebi.ac.uk) sequence alignments of CYP3A4 in human and cattle, 
3A4v2 in Cercopithecus aethiops (African green monkey), 3A44 in mouse, 3A66 in 
Macaca mulatta (rhesus monkey) and 3A45 in Onchorhynchus mykiss (rainbow 
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trout) .  The gene-specific forward primer sequence for 3‟-RACE of turkey 
CYP3A37 was 5‟-TTTGGAASTGGACCCAGRAACTGCATTGGC-3‟. The gene-
specific reverse primer for 5‟-RACE was 5‟-
GCAACTTTCAGAGTCAAGAGAGCAAATCGC-3‟.  All reactions used a 
mixture of two universal primers (long primer: 5‟-
CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3‟ and 
short primer: 5‟-CTAATACGACTCACTATAGGGC-3‟) provided in the BD 
SMART RACE cDNA Amplification Kit (BD Biosciences Clontech, Palo Alto, 
CA).  The full-length turkey CYP3A37 gene was cloned using forward and 
reverse primers designed from the sequence information obtained from 3‟- and 
5‟-RACE (CYP3A37 full-length forward primer: 5‟ 
CTGGGACAGATGGACAGAGAC-3‟, reverse primer: 5‟-
GTACACCAAGAAGAAAGTCACCCATCTC-3‟).   
To identify segregating markers to genetically map CYP3A37 in the turkey 
genome the turkey mRNA (GenBank DQ450083) was aligned with the chicken 
whole genome sequence.  Based on this alignment, primers were designed to 
amplify by PCR the intervening sequence between exons 11 and 12 of the 
CYP3A37 gene.  Primer sequences were as follows; exon11_forward 5‟- 
CCCAGAGGAGTTCAGACCAG-3‟ and exon12_reverse 5‟-
CATCCCAATGCAGTTCCTG -3‟.   This fragment was amplified and sequenced 
from DNA pools representing the F1 generation of the UMN/NTBF mapping 
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families (Reed et al., 2003).  Each DNA pool included three individuals; one sire 
and the two dams to which it had been crossed. Genotypes were then obtained 
for informative families of the UMN/NTBF mapping population by digestion of 
CYP3A37 intron 11 amplicons directly with restriction endonucleases followed 
by electrophoresis in 1% agarose (PCR/RFLP).  Two-point linkage analysis of the 
genotypes for a SNP in intron 11 and markers already placed on the turkey 
linkage map (Reed et al., 2007b) was performed using Locusmap (Garbe and Da, 
2003). 
Analysis of biological activity.  Bicistronic expression constructs 
consisting of the coding sequence of CYP3A37 (GenBank DQ450083) followed by 
that of human NADPH-P450 reductase (hNPR), the redox partner to P450, were 
constructed as described previously (Yip and Coulombe, 2006).  Two variants of 
CYP3A37 were cloned: the wild-type sequence (wtCYP3A37) and an N-terminal 
truncated sequence (tCYP3A37).  Deletion of hydrophobic N-terminal amino 
acids and other modifications have previously shown to increase the expression 
level of P450s in E. coli (Shimada et al., 1997), so we engineered the truncated 
sequence (tCYP3A37) by deleting 11 codons in this region. In addition, the 
nucleotide sequences of first eight codons were modified to enhance protein 
expression (Barnes et al., 1991). A 6X His tag was also added to facilitate 
immunodetection and purification. The expression constructs were created by 
digesting the original pCW1A2/hNPR vector with NdeI and XbaI to excise the 
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CYP1A2 coding sequence. The gel-purified vector fragment was ligated with the 
wild-type or truncated CYP3A37 NdeI- and XbaI-digested, PCR-amplified 
fragment using T4 DNA ligase.  The resulting ligation mix was transformed into 
DH5αF‟IQ cells.  Individual clones were screened by colony PCR and diagnostic 
restriction digestion before being sequenced.  Sequences in the entire reading 
frame of both constructs as well as the 5‟- and 3‟-junctions of the inserts to the 
vectors were verified before individual clones were used in expression.  The final 
expression plasmids were transformed into DH5αF‟IQ cells.  
Heterologous expression of tCYP3A37 in E. coli (Jenkins et al., 1998) was 
carried out by inoculating 5 ml of Luria-Bertani ampicillin medium with a single 
colony of DH5αF‟IQ E. coli transformants, which was then incubated for 23 hr 
with shaking (150 rpm) at 30 C.  Levels of P450 expression were determined by 
reduced CO/reduced difference spectrum (Genesys 6 UV-vis spectrophotometer, 
Thermo Spectronic, Rochester, NY).  E. coli membranes and cytosol were then 
prepared for AFB1 metabolism experiments (Yip and Coulombe, 2006). 
The oxidation activity toward AFB1 was determined by HPLC using 
conditions that we have described previously (Yip and Coulombe, 2006), which 
were optimized in preliminary experiments.  Because of its short half-life, AFBO 
was indirectly measured as the glutathione (GSH)-trapped conjugate, which 
provides an accurate and quantitative measurement (Ramsdell and Eaton, 1990).  
E. coli membranes expressing tP4503A37 (0.307 μM), BHA-induced mouse 
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cytosol (~ 800 μg) as a source of glutathione S-transferase (GST), and 2-250 μM 
AFB1 was added to the assay mixture as substrate.  The reactions were incubated 
at 37 C for 20 min with gentle shaking and stopped by 250 μl of cold MeOH 
spiked with 24 μM aflatoxin G1 (AFG1) as an internal standard.  Metabolite 
formation was calculated by establishing calibration curves between the peak 
areas in the chromatograms and the amounts of metabolites injected, using 
authentic AFBO-GSH HPLC standards.  Kinetic data were analyzed by 
SigmaPlot Enzyme Kinetics Module software (Systat, San Jose, CA) and were fit 
using the Michaelis-Menten equation V = Vmax [S]/([S] + Km) and nonlinear 
regression analysis to calculate the kinetic constants Vmax and Km.   
 
Results 
Sequence and structure of CYP3A37. Sequence analysis of clones that 
covered the entire reading frame of CYP3A37 revealed a sequence of 1512 bp 
coding for 504 amino acids (Figure 2.1).  Like the human homologue, the turkey 
CYP3A37 gene is organized into 13 exons and 12 introns.  The 13 exons of the 
turkey gene were 124, 94, 53, 100, 114, 89, 149 128, 73, 161, 227, 161 and 477 bases 
in length.  Exons 1 and 13 contain 71 and 93 coding nucleotides, respectively.  
Our previous examination of CYP1A5 (Reed et al., 2007a) found identical gene 
structure between the turkey and chicken homologues.  Alignment of the turkey 
CYP3A37 mRNA with the chicken whole genome sequence (release 2.1) indicates 
introns of 2561, 312, 1080, 477, 255, 718, 447, 691, 162, 429, 454, and 120 bases in 
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length (Figure 2.2).  Alignment of the turkey mRNA sequence with that of the 
chicken (NM_001001751, Figure 2.3) indicated 94.2% nucleic acid sequence 
similarity.  Most notably, the turkey CYP3A37 gene was found to be 4 amino 
acids shorter than the chicken homologue due to a 12 bp insertion/deletion in 
exon 9 (Figure 2.1).   In addition to this length difference, 36 amino acid 
substitutions are predicted between chicken and turkey, with 92.8% similarity. 
Genetic mapping of CYP3A37. Intron-containing fragments totaling 560 
bp were sequenced from the turkey DNA pools (Genbank EU216548).  Sequence 
similarity of CYP3A37 intron 11 between the turkey and chicken was 92.4%.   A 
single G > A SNP at position 256 of the 454 bp intron was identified in the F1 
individuals of the UMN/NTBF mapping population.  This polymorphism 
occurred within the recognition sequence of the restriction endonuclease Bsl I (5'-
CCNNNNN▼NNGG-3‟) and this enzyme was used for PCR/RFLP genotyping 
of the mapping families.  Genotypes at the CYP3A37 SNP (256G>A) were 
combined with the markers in the current UMN database (Reed et al., 2007b).  
Linkage analysis of the SNP genotypes (83 informative meioses) revealed 
significant linkage (two-point LOD score >3.0) between the CYP3A37 SNP and a 
microsatellite marker in turkey linkage group M10 (corresponding to chicken 
chromosome 14, GGA14).  Distance between CYP3A37 and MNT323 was 9.9 cM 
(LOD 13.04, Figure 2.3).   
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Activity of E. coli-expressed CYP3A37. Because of their strong 
hydrophobicity in the N-terminal region, wild-type eukaryotic P450s without N-
terminal modifications are often not expressed in E. coli (Guo et al., 1994), and 
wtCYP3A37 was no exception to this observation.  Our approach of producing 
the truncated tCYP3A37 resulted in a relatively high level of protein expression, 
with 300-400 nmol tCYP3A37 per liter of culture, as estimated by the reduced 
CO/reduced difference spectrum of whole cells.  After membrane and cytosol 
isolation, approximately 27% of the tCYP3A37 was recovered in the membrane 
fraction, and 20-40% was in the cytosol fraction.  Membranes from E. coli-
expressing tCYP3A37 also expressed active hNPR, the redox partner necessary 
for P450-mediated catalysis. The activity of hNPR, measured by reduction of 
cytochrome c, was 0.42 µmol/min/mg total protein.   
The P4503A37-expressing E. coli membranes efficiently epoxidated AFB1 
to the exo-AFBO in our HPLC-based in vitro assay.  Formation of this active 
metabolite conformed to Michaelis-Menten kinetics (Figure 2.4). The Km and Vmax 
values of exo-AFB1 formation were 21.6 + 6.4 μM and 1.3 + 0.1  nmol/min/nmol 
P450, respectively (R2 = 0.746).  
 
Discussion 
Biotransformation to AFBO is the necessary first step in the development 
of toxic and carcinogenic activity of AFB1 in animals, and P450s are the most 
important enzymes in this process (Coulombe, 1993).  The adverse effects of 
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AFBO is due to its reactivity toward DNA and other critical cellular 
macromolecules (Guengerich, 2008).  In turkeys, as in humans and other animals, 
AFB1 is bioactivated mainly by P4501A2 and 3A4 homologues (Klein et al., 2000). 
In humans, P4503A4 is the predominant form which epoxidates AFB1 at 
environmentally-relevant substrate concentrations (Kamdem et al., 2006).  Thus, 
the discovery of the CYP3A4 homologue CYP3A37 in turkey liver is of 
substantial importance in discerning the mechanisms of the extreme sensitivity 
of this species to AFB1.  
The structure of CYP3A37 in turkey is markedly similar to that of chicken 
CYP3A37 and the human homologue CYP3A4 with thirteen exons and twelve 
introns.   All 13 exons are, at least in part, translated.  With the exception of exons 
9 and 13, the number of amino acid residues encoded in aligned transcripts is 
conserved among the two poultry species and human.  Turkey exon 13 was one 
residue longer in humans.  The most notable differences occurred in exon 9 in 
which the turkey exon is 12 bp (4 aa) shorter than the corresponding chicken 
sequence.   Interestingly, exon 9 in humans (NM_017460) is similar to that of 
turkey in that it is 18 bp shorter in the same region as the chicken protein.  This 
region, which lies between two helix domains (human resides 271-279 and 292-
323) may be less functionally constrained.  Two alternate-spliced transcripts (503 
and 353 residues) are reported for human CYP3A4.  Splice variants were not 
observed in the turkey.  A search of the NCBI EST database identified 19 
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CYP3A37 transcripts for the chicken, none of which indicated splice variants 
upon alignment.     
Linkage of CYP3A37 to markers in turkey linkage group M10 is consistent 
with the position of CYP3A37 in the chicken whole genome sequence, 
approximately 0.9 Mbp from MNT323. In humans, CYP3A4 is found in a cluster 
with other P450 genes on HGA7q21.1.   In the chicken (and turkey, data not 
shown), a second P450 gene CYP3A80 is found adjacent to CYP3A37.   
Investigations of this P450 gene are ongoing in our laboratory.   
Membranes from E. coli-expressing CYP3A37 efficiently converted AFB1 to 
AFBO.  This confirms our previous observation of the presence of a CYP3A4 
homologue in turkey liver microsomes (Klein et al., 2000).  The kinetic constants 
for exo-AFB formation by tP4503A37 compared to that reported for tP4501A5 
(Yip and Coulombe, 2006) indicate that the former has a higher AFB1 epoxidation 
activity (Km =  21.6 + 6.4 vs. 65 + 12 μM; Vmax =  1.3 + 0.1  vs. 0.61 + 0.04 
nmol/min/nmol P450).  Based simply on these kinetic constants, it is safe to 
assume that CYP3A37 plays an important role in AFB1 bioactivation in turkey 
liver in vivo. However, a confirmation of the relative roles of CYP3A37 and 
CYP1A5 in turkey liver microsomses awaits immunoinhibiton studies which are 
currently underway in this laboratory.  By comparison, lymphoblastoid 
microsomes expressing human CYP3A4 cDNA exhibited slightly different kinetic 
constants than CYP3A37 (Km = 133 μM; Vmax = 6.2 nmol/min/nmol P450) 
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(Gallagher et al., 1994).  Such interspecies rate differences are to be expected, but 
may also be explained by the different expression systems.   
Due to extreme susceptibility of poultry, especially turkeys, to the toxic 
and carcinogenic effects of AFB1, development of molecular markers (SNPs 
and/or microsatellites) in genes coding for critical genes like CYP3A37 will be 
important in tracking susceptibility traits.  Because of the striking similarities 
between the sequences of turkey and chicken, this work can be of benefit to the 
entire poultry industry.  
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Figure 2.1.  Aligned coding regions of turkey (GenBank DQ450083) and chicken 
(GenBank NM_001001751) CYP3A37 cDNAs.  Predicted amino acid sequences 
for each gene are given below the nucleotide sequence.  Exon junctions based on 
alignments with genomic DNA are indicated above the chicken sequence.  
Position (underlined) of PCR primers used in genotyping are indicated. A 12 bp 
deletion in the turkey exon 9 is shown as dashes. 
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Figure 2.2. Idiogram of turkey CYP3A37 indicating position of exons and introns 
as determined by alignment of the turkey mRNA sequence (DQ450083) to the 
chicken whole genome sequence. Location of the 256G>A SNP used for linkage 
mapping is indicated by the arrow. Length of exons (above) and introns (below) 
are presented, coding nucleotides included in exons 1 and 13 are indicated in 
parentheses. 
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Figure 2.3.  Physical map of chicken chromosome 14 (GGA14) based on positions 
(determined by BLASTN) of genetically mapped turkey sequences (Reed et al., 
2007b) aligned with assembly 2.1 of the chicken whole-genome sequence (units = 
bp).
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Figure 2.4. Michaelis-Menten plot for AFB1 oxidation by E. coli membranes 
expressing truncated turkey CYP3A37. Km and Vmax of exo-AFBO formation are 
21.6 + 6.4 μM and 1.3 + 0.1194  nmol/min/nmol P450, respectively (R2 = 0.746). 
Points are mean (± SE), n = 3. 
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CHAPTER 3 
CLONING, EXPRESSION, AND FUNCTIONAL CHARACTERIZATION OF 
CYTOCHROME P450 3A37 WITH HIGH AFLATOXIN B1 EPOXIDATION 
ACTIVITY FROM TURKEY LIVER3  
  
Abstract  
Cytochromes P450 (P450) play an important role in the formation of 
carcinogenic and mutagenic electrophilic intermediates from a wide range of 
xenobiotics, including naturally occurring dietary compounds.  The pathogenesis 
of hepatotoxic and hepatocarcinogenic action of the mycotoxin aflatoxin B1 
(AFB1) involves initial bioactivation by P450s to a reactive and electrophilic 
intermediate exo-aflatoxin B1-8,9-epoxide (exo-AFBO). Poultry, especially turkeys 
are extremely sensitive to AFB1, a condition due, in part, to efficient epoxidation 
by P450 1A and 3A isoforms. We previously reported discovery of CYP1A5 from 
turkey liver, that like its human homologue, CYP1A2, bioactivated AFB1 to exo-
AFBO and aflatoxin M1 (AFM1). Here we describe CYP3A37, the CYP3A4 
homologue from turkey liver. The gene has an open reading frame (ORF) of 1512 
bp, and the protein is predicted to be 504 amino acids with 97% identity to 
chicken CYP3A37. A truncated construct of the turkey CYP3A37 with 11 amino 
acids deleted from the hydrophobic N-terminal region was heterologously 
                                                 
3 Coauthored by Sumit Rawal, Shirley S. M. Yip and Roger A. Coulombe Jr. Submitted for 
publication to the Chemical Research in Toxicology, American Chemical Society.   
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expressed in Escherichia coli, the protein from which exhibited a CO difference 
spectrum typical of P450s. Like human CYP3A4, CYP3A37 biotransformed AFB1 
to exo-AFBO and aflatoxin Q1 (AFQ1) and possessed nifedipine oxidase activity, 
both of which were inhibited by the CYP3A4 inhibitor 17α-ethynylestradiol. 
Oxidation of AFB1 to exo-AFBO and AFQ1 by CYP3A37 followed sigmoidal Hill 
kinetics best described by Eadie-Hofstee plots, suggestive of an allosteric 
interaction between the enzyme and AFB1. CYP3A37 possessed at least two 
binding sites (n = 1.9 for exo-AFBO and 1.6 for AFQ1 products) for AFB1, 
indicative of positive cooperativity. The calculated Km and Vmax values for the 
formation of exo-AFBO were 287 + 21 µM and 1.45 + 0.07 nmol/min/nmol P450, 
respectively, whereas those of AFQ1 formation were 302 + 51 µM and 7.86 + 0.75 
nmol/min/nmol P450, respectively.  These data strongly suggest that CYP3A37, 
along with CYP1A5, plays an important role in AFB1 epoxidation in turkey liver. 
And, this activity plus that of CYP1A5, previously described, likely results in the 
efficient bioactivation of AFB1 that makes turkeys very susceptible to toxicosis. 
 
Introduction 
Cytochrome P450s (P450 for protein; CYP for gene) are the major drug 
metabolism enzymes involved in the metabolism of variety of endogenous and 
exogenous substrates (Parikh et al., 1997). While converting most of the 
compounds into readily excretable detoxified hydrophilic form, P450s also 
contribute to the toxicity of some xenobiotics through bioactivation resulting in 
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the formation of reactive intermediates which causes toxic effects (Guengerich et 
al., 1996a).  The carcinogenic mycotoxin aflatoxin B1 (AFB1) is bioactivated by 
P450s to the electrophilic and highly reactive epoxide intermediate exo-AFB1-8,9-
epoxide (exo-AFBO) (Ball and Coulombe, 1991; Coulombe, 1993; Gallagher et al., 
1996; Guengerich et al., 1996a), which binds to DNA, RNA and cellular proteins 
and is responsible for mediating the toxic and carcinogenic effects of AFB1 in 
humans as well as most animal species.  In many species, glutathione-S-
transferases (GSTs) detoxify the exo-AFBO so produced, by conjugating it with 
endogenous glutathione. 
Poultry, specifically turkeys, are extremely sensitive to aflatoxicosis 
(Carnaghan et al., 1966; Arafa et al., 1981; Giambrone et al., 1985; Huff et al., 1986; 
Kubena et al., 1995; Klein et al., 2000). The susceptibility of turkeys to AFB1 was 
first demonstrated in the early 1960s as the etiological agent of “Turkey X 
disease” which caused widespread deaths of turkeys and other poultry in 
Europe (Stevens et al., 1960). Aflatoxins are ubiquitous in corn-based animal 
feeds, their presence in feed cause significant economic losses to the poultry 
industry every year, and contamination is practically unavoidable (CAST, 1989; 
Coulombe et al., 2005).  
We have previously shown that this extreme sensitivity of turkeys to 
AFB1, is, in part, due to efficient oxidation mediated by homologues to human 
CYP1A2 and CYP3A4 (Klein et al., 2000, 2003; Yip and Coulombe, 2006). We 
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recently amplified CYP1A5 from turkey liver (Yip and Coulombe, 2006), the E. 
coli expressed protein of which, like its human counterpart CYP1A2, oxidized 
AFB1 to exo-AFBO and aflatoxin M1 (AFM1). Although both P450 1A and 3A 
enzymes oxidize AFB1, there are conflicting reports on their relative importance 
(Shimada and Guengerich, 1989; Ramsdell and Eaton, 1990; Gallagher et al., 1994, 
1996). In human liver, CYP3A4, which appears to account for the majority of the 
formation of exo-AFBO and AFQ1, was an important determinant of the AFB1 
disposition (Shimada and Guengerich, 1989; Kamdem et al., 2006).  
We recently elucidated the genetic structure of turkey CYP3A37, which 
like human CYP3A4, is organized into 13 exons and 12 introns (see Chapter 2). 
The exons of the turkey gene were 124, 94, 53, 100, 114, 89, 149, 128, 73, 161, 227, 
163, and 475 bases in length. Exons 1 and 13 contained 71 and 93 coding 
nucleotides, respectively. Because of its presumed role in AFB1 bioactivation, we 
describe here the heterologous expression and functional characterization of this 
CYP3A4 homologue, CYP3A37.  
 
Materials and Methods 
Chemicals and Reagents. QIAprep spin miniprep kit, QIAquick PCR 
purification kit, and gel extraction kit were obtained from Qiagen (Valencia, CA). 
TOPO TA cloning kit and maximum efficiency DH5αF‟IQ Escherichia coli cells 
were from Invitrogen (Carlsbad, CA). Restriction enzymes and T4 DNA ligase 
were from Fermentas (Hanover, MD). Exo- and endo-AFB1-8,9-epoxide 
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glutathione conjugate (AFBO-GSH) standard were a generous gift from Dr. F. 
Peter Guengerich, Vanderbilt University School of Medicine (Nashville, TN). 
Anti-His tag monoclonal antibody was from Novagen (San Diego, CA). The 
Phototope-HRP Western Blot Detection System was from Cell Signaling 
(Beverley, MA). Rabbit polyclonal anti-CYP3A37 serum was raised against the 
peptide sequence “SQKSDSDGKNSHKA” (amino acids 278-291) by Genemed 
Synthesis (San Antonio, TX). This peptide sequence was selected by the 
manufacturer while taking into consideration that it should be antigenic, 
hydrophilic and readily accessible. All other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO). 
Rapid amplification of cDNA ends (RACE). The CYP3A37 gene was 
amplified from 1-day-old male turkey liver by 3‟-5‟-RACE procedures described 
previously (Yip and Coulombe, 2006; Chapter 2). In brief, small segments of 
RNA later stored turkey liver were homogenized and RNA isolated using Poly 
(A) Pure mRNA purification kit (Ambion, Austin, TX). Isolated RNA was further 
used as a RACE template. The RACE procedure as mentioned in BD SMART 
RACE cDNA Amplification Kit (BD Biosciences Clontech, Palo Alto, CA) was 
followed.  Primers used in 3‟-RACE were designed based upon the sequence 
alignment of CYP3A4 in human and cattle, 3A4v2 in Cercopithecus aethiops 
(African green monkey), 3A44 in mouse, 3A66 in Macaca mulatta (rhesus monkey)  
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and 3A45 in Onchorhynchus mykiss (rainbow trout) 4 using ClustalW 
(www.ebi.ac.uk). 5‟-RACE primers were designed based on sequences of 3‟-
RACE as well as the sequence alignments. Products of the PCR were cloned into 
pCR 4-TOPO vector and sequenced at the CORE facility at Utah State University. 
Sequences were analyzed by Lasergene SeqMan II software (DNASTAR Inc., 
Madison, WI).    
Construction of expression plasmid and bacterial expression. An E. coli 
based recombinant P450 system was used for CYP3A4 homologue identification 
(Yip and Coulombe, 2006). Expression vector construction was as described 
previously (Yip and Coulombe, 2006). We chose pCW vector, developed by the 
laboratory of Prof F. W. Dahlquist (Gegner and Dahlquist, 1991), which contains 
two tac promoter (inducible by isopropyl-β-D-thiogalactopyranoside: IPTG) 
cassettes upstream of an NdeI (CATATG) restriction enzyme cloning site 
coincident with the initiation ATG codon. This vector contains a strong 
transcription termination mechanism and a phage M13 origin of DNA 
replication. Transcription prior to the addition of inducing agents is inhibited by 
LacI gene encoding a lac repressor molecule. The original bicistronic 
pCW1A2/hNPR vector developed by Dr. F. Peter Guengerich was generously 
provided by Dr. Gary Yost, University of Utah (Salt Lake City, UT). Bicistronic 
                                                 
4 GenBank accession numbers for the CYP3A enzymes cited in this article are as follows: Human 
CYP3A4: BC069418, Bos taurus (cattle): NM_174531, Cercopithecus aethiops (African green 
monkey): DQ022198, Mus musculus (house mouse): AB039380, Macaca mulatta (rhesus monkey): 
AY635466, Oncorhynchus mykiss (rainbow trout): AF267126.  
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expression constructs consisting of the coding sequence of CYP3A37 followed by 
human NADPH-P450 reductase (hNPR), the redox partner to P450, were 
constructed as described (Yip and Coulombe, 2006; Chapter 2). Cytochrome 
P450s are difficult to express in their native form due to the hydrophobic amino 
acid rich N-terminal region, so a truncated version of the gene was constructed 
to enhance its expression in E. coli (Barnes et al., 1991) (Figure 3.1). Specifically 11 
codons were deleted in the N-terminus and the first 8 codons had a modified 
nucleotide sequence to enhance its expression. A 6X-His tag was added in the C-
terminal region to facilitate immunodetection and purification (Crowe et al., 
1994). The original pCW1A2/hNPR vector was digested with NdeI and XbaI to 
excise the CYP1A2 coding sequence for the construction of expression constructs. 
Clones of CYP3A37 digested with NdeI and XbaI were ligated with the gel-
purified vector fragment and PCR-amplified using T4 DNA ligase. This ligation 
mix was transformed into DH5αF‟IQ cells. Heterologous expression of CYP3A37 
in E. coli was performed (Jenkins et al., 1998). A single colony of DH5αF‟IQ E. coli 
transformants was inoculated in to five milliliters of Luria-Bertani ampicillin 
medium. It was then allowed to grow overnight at 37 ºC with vigorous shaking. 
450 mL of modified Terrific-Broth ampicillin medium with trace elements was 
then used for further inoculation of the starter culture at 1:100 dilutions. Cultures 
were grown at 37 ºC to an OD600 of 0.3-0.5. After an equilibration step of 30 min 
at 30 ºC, induction was initiated by adding 1 mM IPTG. δ-aminolevulinic acid 
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(0.5 mM) was also added to the cultures. Cells were incubated at 30 ºC with 
shaking (150 rpm), harvested after 23 h and amounts of P450 expression were 
determined by reduced CO/reduced difference spectra (Omura and Sato, 1964) 
(Spectronic GENESYS 6 UV-Vis spectrophotometer, Thermo Spectronic, 
Rochester, NY). E. coli membranes and cytosol were prepared as described (Yip 
and Coulombe, 2006). All kinetic assays were performed with CYP3A37 E. coli 
membranes.  
Immunodetection of recombinant CYP3A37. E. coli membranes 
expressing CYP3A37, control vector (pCWOri+ without P450 and reductase 
inserts) and turkey liver microsomes were run on a 4-15% Tris-HCl Ready Gel 
(Bio-Rad). Immunoblotting was performed according to the supplier‟s 
instructions (Qiagen, Valencia, CA). To reduce the extraneous bands caused by 
the recognition of bacterial proteins, the rabbit polyclonal anti-CYP3A37 serum   
was first preadsorbed by pCWOri+ E. coli membranes (Guengerich et al., 1996b; 
Yip and Coulombe, 2006). Briefly, 120 µL of pCWOri+ membranes (22 mg 
protein) were added to 2 mL antiserum (111 mg protein) and incubated at 4 ºC 
for 2.5 h for preadsorption. The samples were centrifuged at 13000g for 10 min at 
4 ºC and supernatants were used as primary antibody (1:4000). HRP-conjugated 
goat anti-rabbit IgG (1:5000) were used as secondary antibody. 
Chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Pierce, 
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Rockford, IL) signal detection and images were captured using Nucleovision E20 
Imaging Workstation (Nucleotech, Hayward, CA). 
Quantification of AFB1 metabolites. The exo-AFBO intermediate is 
unstable and has a short half-life, so it was determined indirectly as a stable, 
trapped AFBO-GSH conjugate using conditions we have described previously 
(Ramsdell and Eaton, 1990; Yip and Coulombe, 2006). A reaction mixture 
consisting of E. coli membranes expressing CYP3A37 (0.709 µM), butylated 
hydroxyanisole (BHA)-induced mouse cytosol (~800 µg total protein) as a source 
of GST, 2 mM NADPH, 5 mM GSH and 0.1-1000 µM AFB1 in spectral grade 
dimethyl sulfoxide (DMSO) was made in epoxide trapping buffer (5 mM MgCl2, 
25 mM KCl, 0.25 mM sucrose, and 80 mM potassium phosphate, pH 7.6) to give a 
final volume of 250 µL. The reactions were incubated at 37 ºC for 20 min with 
gentle shaking and stopped by adding 250 µL of cold methanol spiked with 24 
µM aflatoxin G1 (AFG1) as an internal standard. Inhibitor or anti-CYP3A37 
antibodies whenever used were incubated with the membranes for 10 min in an 
ice-bath before adding other components of the reaction. This treatment was 
done to provide extra time for the inhibitor or the antibody to bind to the 
enzyme. The samples were kept overnight at -20 ºC to facilitate protein 
precipitation and then centrifuged at 13000g for 10 min. The supernatant was 
filtered through a 0.2 µm nylon membrane before 100 µL was injected into the 
HPLC. Metabolites were separated on a Shimadzu LC system (Shimadzu, 
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Pleasanton, CA) equipped with a model LC-20AD pump, a model SPD-20AV 
UV-Vis detector, and an Econosphere C18 (150 mm X 4.6 mm) column (Alltech 
Associates, Deerfield, IL) which was kept at 40 ºC. The eluate was monitored by 
UV absorbance (λ = 254 nm). The mobile phases used in this assay were as 
described previously (Klein et al., 2000). Metabolites were quantified by 
establishing calibration curves between the peak areas in the chromatograms and 
the amounts of metabolites injected, using authentic AFBO-GSH and AFQ1 
standards. 
Nifedipine oxidase activity. Nifedipine oxidase was determined as 
described previously (Kelly et al., 1997). Inhibitors or anti-CYP3A37 antibodies 
were tested on this activity in a similar way as described above. 
Data analysis. Kinetic data were analyzed by SigmaPlot Enzyme Kinetics 
Module software (Systat, San Jose, CA). Data for exo-AFBO and AFQ1 formation 
were analyzed by nonlinear regression using the general allosteric model, the 
Hill equation to calculate Vmax and Km [V= Vmax [S]n/ ([Km]n + [S]n)]. In this 
equation, n represents the number of apparent binding sites.  
 
Results 
RACE. Sequence analysis revealed that this gene has an ORF of 1512 bp 
coding for 504 amino acids. In addition, it had 53 bp in the 5‟-untranslated region 
(UTR) and 384 bp in the 3‟-UTR, with a total of 1949 bp (Figure 3.2). Predicted 
molecular mass of this CYP3A4 homologue is 58 kDa. The heme-binding motif, 
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usually represented as FXXGXXXCXG, was identified in CYP3A37 as 
FGAGPRNCIG (Figure 3.2). Sequence identity comparison of this gene and 
CYP3A class genes in other species is shown in Table 3.1. These comparisons, 
which were made using EMBOSS-Align program (www.ebi.ac.uk), revealed that 
this gene has 93% and 92% nucleic acid and amino acid identity, respectively, to 
the chicken CYP3A37 (Ourlin et al., 2000), and was thus assigned as CYP3A37 by 
Dr. David Nelson of the University of Tennessee. 
Bacterial Expression and Immunodetection. As frequently observed with 
unmodified P450s (Guo et al., 1994), the wild-type CYP3A37 was not expressed 
as detectable P450 as determined by reduced CO/reduced difference spectrum 
(Omura and Sato, 1964). The truncated tCYP3A37 expressed 250-400 nmol of 
CYP3A37 per liter of the culture, as determined by the CO difference spectra of 
whole cells. CYP3A37 was recovered in both membrane and cytosol, 
approximately 26% and 25-45%, respectively. The rest of the amounts were lost 
in differential centrifugation procedure used for the isolation of membrane and 
cytosolic fractions. E. coli membranes expressing recombinant CYP3A37 also 
expressed active hNPR (0.54 µmol/min/mg total protein) as measured by 
cytochrome c reduction. As compared to the activity of purified hNPR expressed 
in E. coli from the same plasmid (50 µmol/min/mg), we determined that hNPR 
was comprised of 2.8% (w/w) of the proteins in tCYP3A37 E. coli membrane (vs 
8% for P450), which corresponded to a hNPR-to-P450 molar ratio of about 1:4. 
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Polyclonal anti-CYP3A37 antibodies detected a band with an apparent molecular 
mass of 58 kDa in E. coli expressed CYP3A37 and in turkey liver microsomes 
(Figure 3.3). 
AFB1 Oxidation and Nifedipine Oxidase activity. E. coli-expressed 
CYP3A37 oxidized AFB1 to exo-AFBO and AFQ1, and a plot of V vs. S, exhibited a 
sigmoidal relationship, suggesting that the formation of both products is driven 
by an allosteric interaction between AFB1 and CYP3A37, showing positive 
cooperativity (Figure 3.4A). The data were analyzed by the general allosteric 
model using the Hill equation, and the resultant Eadie-Hofstee plots are shown 
in Figures 3.4B (for exo-AFBO formation) and 3.4C (AFQ1). The n (apparent 
number of binding sites) values for the formation of exo-AFBO and AFQ1 were 
1.9 and 1.6, respectively, suggesting the presence of at least two binding sites for 
AFB1 on CYP3A37 (Table 3.2). The mean dissociation constant (Km) for the two 
sites was 295 µM.  
 Like human CYP3A4 (Yamazaki et al., 1996), CYP3A37 possessed 
nifedipine oxidase activity which, unlike AFB1 metabolism, conformed to simple 
Michaelis-Menton kinetics. The Km and Vmax for this activity were 1.4 + 0.5 µM 
and 1465 + 289 nmol/min/nmol P450 (r2 = 0.84), respectively (Figure 3.5). 
Inhibition by specific P450 inhibitors and anti-CYP3A37 antibodies. The 
effects of specific inhibitors to mammalian P450s on exo-AFBO formation as well 
as on nifedipine oxidase activity were examined. The specific CYP3A4 inhibitor 
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17α-ethynylestradiol was the most effective of those tested, completely inhibiting 
the formation of exo-AFBO at a concentration of 200 µM (IC50 = 40 µM) (Figure 
3.6). Erythromycin, a CYP3A1/4 inhibitor was moderately effective. Inhibitors to 
other P450s were either slightly or not effective (Figure 3.6). At the same 
concentrations, 17α-ethynylestradiol also inhibited nifedipine oxidase activity 
(IC50 = 74 µM) (Figure 3.7). Anti-CYP3A37 antibodies inhibited the formation of 
both exo-AFBO and nifedipine oxidase activity, as shown in Figure 3.8.  
 
Discussion 
Many P450s bioactivate xenobiotics, like AFB1, converting them into 
highly reactive electrophilic intermediates, which cause mutation and 
carcinogenesis. Although AFB1 is metabolized by P450s to endo- and/or exo-
AFBO, it is the exo- stereoisomer which binds to DNA, RNA and other cellular 
macromolecules to elicit the toxic responses to this mycotoxin (Raney et al., 1992). 
The extreme sensitivity of turkeys to AFB1 is due, at least in part, to hepatic P450s 
with high epoxidation activity. In turkey liver microsomes, both CYP1A and 3A 
homologues are responsible for the metabolism of AFB1 to the toxic and 
carcinogenic exo-AFBO, as it occurs in humans and other animals (Klein et al., 
2000; Yip and Coulombe, 2006; Chapter 2). Here, we report that turkey liver 
possesses CYP3A37, a homologue to human CYP3A4 with AFB1 epoxidation and 
nifedipine oxidase activity.  
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The nucleic acid sequence of this gene was remarkably similar to chicken 
CYP3A37 (Ourlin et al., 2000), with 93% identity. While the sequence of this gene 
was 66% identical to human CYP3A4, the catalytic activity of the E. coli expressed 
CYP3A37 closely resembled that of its human counterpart. Turkey CYP3A37 
possessed activity towards prototypical CYP3A4 substrate nifedipine (Yamazaki 
et al., 1996) and also oxidized AFB1 in a manner similar to human CYP3A4 
(Gallagher et al., 1996). Inhibition of the catalytic activities of CYP3A37 by 17α-
ethynylestradiol further support it‟s designation as a CYP3A4 homologue.  
 Generally P450s require alterations in the hydrophobic N-terminal 
nucleotide sequence (5‟- end) to facilitate translation by E. coli (Barnes et al., 
1991). The N-terminal truncated sequence of wild-type CYP3A37 was produced 
by deleting 11 codons and modifying the nucleotide sequence of the first 8 
codons to facilitate translation by E. coli. These modifications are reported to 
reduce the free energy for base pairing while inhibiting the formation of 
secondary structures by mRNA, which could inhibit translation (Guengerich et 
al., 1996a). Subsequently, truncated CYP3A37 expressed in E. coli produced 
substantial amounts of active P450, which was confirmed by immunoblots 
showing a band of apparent molecular mass of about 58 kDa. The addition of 
hNPR, in our bicistronic constructs, ensured efficient electron transfer to P450: 
the hNPR-to-P450 ratio in the E. coli membranes was 1:4, similar to that we 
previously reported for turkey CYP1A5 (Yip and Coulombe, 2006) and greater 
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than previously reported ratios of 1:5-20 in mammalian liver microsomes 
(Estabrook et al., 1971; Shephard et al., 1983; Parikh et al., 1997).  
Striking similarities between the catalytic activities of E. coli expressed 
turkey CYP3A37 and human CYP3A4 were observed.  For example, turkey 
CYP3A37 efficiently metabolized AFB1 to exo-AFBO and AFQ1 and also 
possessed nifedipine oxidase activity, as does the human enzyme. Furthermore, 
these catalytic activities were completely inhibited by CYP3A4 specific inhibitor 
17α-ethynylestradiol. It must be emphasized that P450 prototypical substrates 
and inhibitors used in this study were developed for mammalian P450s, and 
specificities of these compounds for avian P450s have not been rigorously 
validated.  Erythromycin, an inhibitor to CYP3A1/4, also inhibited the formation 
of exo-AFBO as well as nifedipine oxidase activity, but at concentrations higher 
than that observed for 17α-ethynylestradiol (> 800 µM). While 17α-
ethynylestradiol efficiently inhibited catalytic activities of CYP3A37, 
erythromycin was moderately effective, which may be explained by interspecies 
differences among P450 enzymes.      
This metabolic specificity of CYP3A37 confirms our previous observation 
of the involvement of a CYP3A4 homologue (along with a CYP1A2 homologue) 
in AFB1 bioactivation in turkey liver microsomes (Klein et al., 2000; Yip and 
Coulombe, 2006). Similar to what we previously reported for CYP1A5, turkey 
CYP3A37 resembled its human counterpart with respect to metabolite profile, 
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and to the kinetics of AFB1 oxidation. Like human CYP3A4, CYP3A37 catalysis of 
AFB1 is driven by an allosteric interaction, showing positive cooperativity. 
Human CYP3A4 is reported to have a large and conformationally dynamic active 
site which can accommodate multiple substrates or effector molecules, the 
binding of which leads to allosteric kinetic behavior in that substrate binding to 
CYP3A4 facilitates binding of additional molecules of substrate, enhancing 
turnover (Roberts and Atkins, 2007). Similar to human CYP3A4 (Gallagher et al., 
1996), CYP3A37 possessed at least two binding sites for AFB1.The Km values 
determined for CYP3A37 were almost two-fold greater than those for human 
CYP3A4 [302 µM vs. 139 µM for AFQ1; 287 µM for exo-AFBO in our study vs. 133 
µM for AFBO reported by (Gallagher et al., 1996)], though this comparison is not 
accurate since those authors (Gallagher et al., 1996), did not distinguish the endo- 
and exo- isomers. The Vmax value of AFQ1 formation was almost 8-fold lower for 
CYP3A37 than those of human CYP3A4 (7.86 vs. 61 nmol/min/nmol P450), 
while that of exo-AFBO formation in our study was more than 4-fold lower than 
that of the AFBO formation measured for human CYP3A4 (1.45 vs. 6.2 
nmol/min/nmol P450) (Gallagher et al., 1996). Such kinetic differences could be 
explained by interspecies variations of P450s, but is more likely due to different 
in vitro systems used to model enzyme activity.     
Although CYP3A37 and turkey CYP1A5 (Yip and Coulombe, 2006), 
exhibited different kinetics, a comparison of the kinetic constants of exo-AFBO 
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formation suggests that the former may be more efficient. The Vmax of CYP3A37 
is more than two times that of CYP1A5 (1.45 + 0.07 vs. 0.61 + 0.04 
nmol/min/nmol P450). However, it must be emphasized that the affinity of 
CYP3A37 for AFB1 may be 4-fold lower than that of CYP1A5, as indicated by 
their Km values (287 ± 21 vs. 65 + 12 µM).  
While there are conflicting reports as to which isoform is more important 
in humans in activating AFB1 (Shimada and Guengerich, 1989; Ramsdell and 
Eaton, 1990; Gallagher et al., 1994, 1996), some reports suggest that human 
CYP1A2 is more active at submicromolar substrate concentrations because of its 
high affinity for AFB1, whereas CYP3A4 activates AFB1 at higher concentrations 
(>50 µM) (Crespi et al., 1991; Gallagher et al., 1996). Indeed a similar finding was 
observed previously in our laboratory in human bronchial cells expressing CYP 
1A2 and 3A4 (Van Vleet et al., 2002).  
In conclusion, CYP3A37 is important in mediating toxicity of AFB1 in 
turkeys. This gene was heterologously expressed in E. coli, in quantities sufficient 
to support the catalytic activities, which were similar to the human CYP3A4. 
Because of the role of human CYP3A4 in AFB1 oxidation to exo-AFBO (Shimada 
and Guengerich, 1989; Gallagher et al., 1996; Kamdem et al., 2006), we believe that 
the identification of this homologue from turkeys is important in discerning the 
mechanisms of extreme sensitivity of this species to AFB1. Of particular 
importance was the metabolism of AFB1 by the E. coli expressed protein to exo-
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AFBO and AFQ1. Exo-AFBO, a highly reactive electrophilic intermediate, is 
responsible for carcinogenic and mutagenic effects of AFB1. Thus, we conclude 
that CYP3A37 along with CYP1A5 plays an important role in the extreme 
sensitivity of turkeys to AFB1. 
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Table 3.1. Nucleic acid and amino acid sequence identity and similarity between 
turkey CYP3A37 and other CYP3As (EMBOSS-Align).   
           Nucleic acid  Amino acid 
       
       
Cytochrome P450 Species % Identity  % Identity % Similarity* 
      
      
CYP3A37  Chicken 93  92 97 
CYP3A Xenopus 64  56 75 
CYP3A13 Rat 67  62 79 
CYP3A13 Mouse 67  60 79 
CYP3A4 Human  66  58 76 
CYP3A5 Human 66  58 76 
      
*Percentage similarity of amino acid sequence was determined based on 
EBLOSUM62 matrix. 
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Table 3.2. Hill Equation kinetic constants for CYP3A37 catalyzed AFB1 oxidation 
in E. coli expressed CYP3A37, at AFB1 concentrations of 0.1-1000 µM. “n” is 
number of apparent binding sites. Vmax and Km measured as nmol/min/nmol 
P450 and μM, respectively.  
*3 replicates were used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolite Vmax ± SE* Km ± SE* n ± SE* R2 
exo-AFBO 1.45 ± 0.07 287 ± 21 1.9 ± 0.18 0.98 
AFQ1 7.86 ± 0.75 302 ± 51 1.6 ± 0.26 0.96 
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Figure 3.1. Expression constructs of CYP3A37 showing nucleic acid and amino 
acid sequences at the N- and C-terminals. Wild-type (wtCYP1A5) has 1512 bp 
encoding 504 amino acids; the truncated construct (tCYP1A5) has 1479 bp 
encoding 493 amino acids.  Six histidines were added at the C-terminals to 
facilitate detection and purification. Nucleotides and amino acids different from 
the wild type sequence are bolded. 
 
 
 
 
 
 
 
 
 
 
 
wtCYP3A37:5’- ATGAATTTATTACCTTTTTTTTCTATTGAAACCTGGATACTCTTG 
               M  N  L  L  P  F  F  S  I  E  T  W  I  L  L 
 
tCYP3A37: 5’- ATGGCT     11 amino acids deleted            TTATTA 
               M  A                                   L  L 
 
wtCYP3A37:    CTTATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTT 
               L  I  F  V  A  L  L  I  A  Y  G  T  W  P  F        
 
tCYP3A37:     TTAATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTT 
               L  I  F  V  A  L  L  I  A  Y  G  T  W  P  F 
 
wtCYP3A37:   510aa not shown AATGCCAAGGCACATCACCATCACCATCACTGA-3’ 
              ----------   N  A  K  A  H  H  H  H  H  H STP 
 
tCYP3A37:                 AATGCCAAGGCACATCACCATCACCATCACTGA-3’ 
              ----------   N  A  K  A  H  H  H  H  H  H STP  
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                                                     M  N  L  L  P  F  F  S  I   
AGATGGACAGAGACATACGGACAGACCTCCAAGCCAACTAGAGGAGAGCCACGATGAACCTTCTTCCTTTCTTCTCCATT 80 
E  T  W  I  L  L  L  I  F  V  A  L  L  I  A  Y  G  T  W  P  F  G  L  F  K  K  L   
GAAACCTGGATCCTCTTGCTTATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTTGGGCTGTTCAAGAAGCT 160     
 G  I  P  G  P  R  P  L  P  F  F  G  T  C  L  E  Y  R  K  G  F  L  E  F  D  T  E 
GGGCATTCCTGGGCCAAGACCTCTGCCTTTCTTTGGGACGTGCCTGGAATACCGTAAAGGCTTCTTGGAATTTGACACTG 240   
  C  F  K  K  Y  G  K  I  W  G  I  Y  D  G  R  Q  P  A  V  V  V  M  D  P  Q  I             
AGTGCTTCAAGAAGTATGGGAAAATCTGGGGGATTTACGATGGCAGGCAGCCTGCAGTGGTTGTCATGGACCCCCAGATC 320 
I  K  T  V  L  V  K  E  C  Y  S  T  F  T  N  R  R  R  V  D  L  A  G  E  L  R  N     
ATCAAAACCGTGCTGGTGAAAGAGTGCTACTCCACCTTCACCAACCGCAGGCGCGTAGATCTAGCAGGGGAGCTGAGAAA 400  
 A  V  S  L  A  E  D  D  Q  W  K  R  L  R  T  V  L  S  P  T  F  T  S  G  K  L  K 
TGCTGTCTCATTAGCTGAAGACGATCAGTGGAAAAGGCTCCGTACTGTGCTCTCTCCAACCTTCACCAGTGGGAAGCTAA 480   
  E  M  F  P  T  M  K  H  F  G  E  M  L  V  K  N  V  Q  K  R  V  E  K  D  S  S      
AGGAGATGTTTCCTACAATGAAGCACTTTGGGGAGATGTTGGTGAAAAATGTTCAAAAGAGGGTGGAAAAGGACAGCTCT 560 
V  P  V  K  D  F  F  G  S  Y  S  M  D  V  V  T  S  T  S  F  G  V  N  I  D  S  M  
GTCCCTGTGAAGGACTTCTTTGGAAGCTACAGCATGGATGTAGTCACCAGCACTTCCTTCGGTGTGAACATCGACTCCAT 640    
 N  N  P  K  S  P  F  V  R  E  M  Q  K  L  T  K  F  D  F  F  D  P  L  F  I  L  A  
GAACAACCCTAAAAGCCCCTTTGTCAGAGAGATGCAGAAACTGACCAAGTTTGATTTTTTTGATCCACTCTTCATCTTGG 720    
  F  V  C  P  F  L  T  P  L  M  A  K  M  N  V  S  F  F  P  S  D  A  V  D  F  F             
CATTTGTATGCCCATTCCTTACCCCTCTTATGGCCAAGATGAACGTCAGCTTTTTCCCAAGTGATGCTGTAGATTTCTTC 800 
L  R  S  I  D  K  I  K  K  D  R  E  K  E  T  H  K  G  R  V  D  F  L  Q  M  M  I    
CTGAGGTCTATTGACAAAATTAAGAAGGACCGTGAAAAGGAGACTCACAAGGGCAGAGTAGATTTTCTGCAGATGATGAT 880    
 E  S  Q  K  S  D  S  D  G  K  N  S  H  K  A  L  S  D  I  E  V  L  S  Q  A  F  I  
CGAATCCCAGAAATCAGACAGCGATGGGAAGAACTCACATAAAGCCCTGAGTGACATAGAGGTCCTGTCACAAGCATTCA 960    
  F  I  F  A  G  Y  E  P  T  S  N  T  L  C  Y  L  A  Y  L  L  A  L  H  P  D  V            
TCTTCATTTTTGCTGGCTATGAGCCCACCAGTAACACACTTTGTTACCTGGCTTACCTGCTGGCCTTGCATCCTGATGTA 1040 
Q  Q  K  V  V  N  E  I  D  T  I  L  P  N  K  A  P  L  T  Y  E  A  I  M  Q  L  D   
CAGCAGAAGGTGGTGAATGAAATAGATACCATTCTACCCAACAAGGCTCCGCTCACATATGAAGCGATAATGCAGTTGGA 1120  
 Y  L  D  M  A  V  N  E  T  L  R  L  Y  P  L  G  G  R  I  E  R  T  C  K  K  D  V        
TTACCTTGACATGGCCGTGAATGAAACCCTCCGGCTCTATCCCCTCGGAGGACGGATTGAGAGAACCTGCAAGAAAGATG 1200   
  E  I  N  G  V  T  I  P  K  E  T  I  V  V  I  P  P  Y  T  L  H  R  N  S  E  Y         
TGGAAATAAACGGGGTGACCATTCCAAAAGAAACCATTGTCGTTATCCCACCTTACACCCTGCACCGCAACTCCGAGTAC 1280 
W  P  N  P  E  E  F  R  P  E  R  F  S  K  E  N  K  D  N  I  D  P  Y  T  Y  L  P     
TGGCCAAACCCAGAGGAGTTCAGACCAGAAAGGTTCAGTAAGGAAAACAAAGACAACATAGACCCATACACATACCTGCC 1360   
 F  G  A  G  P  R  N  C  I  G  M  R  F  A  L  L  T  L  K  V  A  I  T  S  I  L  Q         
TTTTGGAGCTGGTCCCAGGAACTGCATTGGGATGCGATTTGCTCTCTTGACTCTGAAAGTTGCCATCACTTCCATATTGC 1440  
  H  F  T  F  Q  V  C  K  E  T  Q  I  P  L  K  L  L  S  M  G  L  M  T  P  E  K       
AGCACTTCACCTTCCAGGTCTGCAAAGAAACTCAGATCCCTCTCAAGCTGCTCTCGATGGGACTCATGACTCCAGAGAAG 1520 
P  I  I  L  K  L  V  P  R  T  N  N  A  K  A  *  
CCCATCATTCTCAAGTTAGTCCCTCGGACCAACAATGCCAAGGCATAGAACCCAACTGTGTCCTGCTGCAGTCTAATGAA 1600  
 
CCCTATGCTAACAAAGGGGTCACACACTGCAGGAAAACTCTCATACGTGTGCAGACACAGAAGTGCAACTTAGCTAATTC 1680  
 
TAGAAGCAATTACTACATATTTACCAAATAACAGCTGTCAGAAATGTAATGTGGATCACTGGGCAGTGGCAATGCACAGC 1760 
 
CCCCTTCATTTGATTGCAGAAATTGAGAAATAAATCCAAATGAGAAGCTGATCATCCACTCCCTTCTAAGGAGACTTCTC 1840   
        
CATCTGGAAAGAAGGAATTATTGTGGCATTCAAGAGAAACAAGGTGTGATGGAAACGCAAATCGCTAGAGCTCGCTGGGC 1920  
 
AGAGATGGGTGACTTTCTTCTTGGTGTAC                                                    1949 
 
Figure 3.2. Complete cDNA and predicted amino acid sequence of turkey 
CYP3A37, with 5‟- and 3‟-UTRs. ORF: 1512bp encoding 504 aa; 5‟-UTR: 53 bp; 3‟-
UTR: 384 bp; total cDNA length: 1949 bp. Start and stop codons are bolded, the 
heme-binding motif, usually represented as FXXGXXXCXG is underlined. 
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Figure 3.3. Immunoblot showing 60 kDa bands in both turkey liver microsomes 
and in CYP3A37-expressing E. coli membranes.  A minor band which was 
detected at around 80 kDa was presumably a bacterial protein, present in E. coli 
membranes of CYP3A37 and in those of pCWOri+ (the empty vector control). 
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Figure 3.4. Kinetics of AFB1 oxidation by E. coli expressed CYP3A37. A sigmoidal 
relationship between substrate concentration and product formation was 
observed, suggesting exo-AFBO and AFQ1 formation are driven by an allosteric 
interaction between CYP3A37 and AFB1, showing positive cooperativity. The 
data was analyzed by Hill‟s equation. (A) V vs. S plot of exo-AFBO and AFQ1 
formation (B) Eadie-Hofstee plot of exo-AFBO formation (C) Eadie-Hofstee plot 
of AFQ1 fromation. Points are mean (+ SE), n=3.  
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Figure 3.5. Nifedipine Oxidase activity of E. coli membranes expressing 
CYP3A37. Activity followed Michaelis-Menton kinetics with parameters: Vmax = 
1465 + 289 nmol min/ nmol/ P450, Km = 1.4 + 0.5 µM (R2 = 0.84). Points are mean 
(+ SE) (n=3). 
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Figure 3.6. Inhibition of AFB1 oxidation to exo-AFBO by E. coli expressed 
CYP3A37, using specific inhibitors to P450s. CYP3A4 prototype inhibitor 17α-
ethynylestradiol inhibited formation of exo-AFBO (IC50 = 40 µM). Erythromycin 
was less efficient. Inhibitors to other mammalian CYPs were either slightly or not 
effective. Points are mean (n=3). 
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Figure 3.7. Inhibition of nifedipine oxidase activity of E. coli expressed CYP3A37 
by specific inhibitors to P450s. 17α-ethynylestradiol, a specific inhibitor to 
CYP3A4 inhibited nifedipine oxidase activity of E. coli expressed CYP3A37 (IC50 
= 74 µM). Erythromycin was less effective. Points are mean (n=3). 
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Figure 3.8. Inhibition of CYP3A37 mediated AFB1 epoxidation and nifedipine 
oxidase activity by anti-CYP3A37 antibodies (5 µg/ml/nmol P450). Points are 
mean (n=3).   
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CHAPTER 4 
METABOLISM OF AFLATOXIN B1 IN TURKEY LIVER MICROSOMES: THE 
RELATIVE ROLES OF CYTOCHROME P450S 1A5 AND 3A37 
 
Abstract 
The extreme sensitivity of turkeys to aflatoxin B1 (AFB1), is associated with 
an efficient epoxidation by hepatic microsomal cytochrome P450s 1A5 and 3A37 
to the toxic exo-aflatoxin B1-8,9-epoxide (exo-AFBO). The combined presence of 
1A5 and 3A37 in the turkey liver, both of which metabolize AFB1 to the exo-
AFBO and to detoxification products AFM1 and AFQ1, respectively, complicates 
the kinetic analysis of the oxidation of this mycotoxin in turkey liver microsomes 
(TLMs).  Furthermore, 1A5 and 3A37 follow Michaelis-Menton and Hill‟s 
kinetics, respectively. In the present study, we examined the reaction kinetics of 
AFB1 oxidation in TLMs, using antisera directed against CYP1A5 and 3A37, for 
the purpose of identifying the isoform responsible for epoxidating AFB1 at 
relatively low concentrations. Pretreatment with anti-CYP1A5 inhibited exo-
AFBO formation, which was especially marked at low, submicromolar (~0.1 µM), 
while anti-CYP3A37 immune serum inhibited exo-AFBO formation, which was 
most evident at much higher (> 50 µM) AFB1 concentrations. At 0.1 µM  AFB1 , 
which is close to the range seen in the livers of animals exposed to AFB1 
concentrations typically occurring in foods and feeds, CYP1A5 contributed to 
about 98% of the total exo-AFBO formation. At this concentration, CYP1A5 was 
 87 
responsible for a much higher ratio (50:1) of activation to detoxification product 
(exo-AFBO: AFM1) compared to CYP3A37. Kinetic constants indicated that 
CYP1A5 acts as the higher affinity, while CYP3A37 as the lower affinity isoform 
for AFB1. In total, the data presented here support the conclusion that CYP1A5 is 
the dominant enzyme responsible for AFB1 bioactivation and metabolism at real-
world AFB1 concentrations, and therefore plays an important role in the extreme 
sensitivity of turkeys to aflatoxicosis.      
 
Introduction  
Aflatoxins, which are toxic and carcinogenic mycotoxins produced by 
Aspergillus fungi, are a major public health concern, especially in geographies 
where AFB1 contaminated foods constitute a staple diet.  Aflatoxin B1 (AFB1) is 
the most toxic and carcinogenic of all aflatoxins (Wogan et al., 1974; Wong and 
Hsieh, 1976; Bondy and Pestka, 2000). AFB1 is not toxic per se, but requires 
bioactivation by P450s to the electrophilic and toxic intermediate exo-AFB1-8,9-
epoxide (exo-AFBO) (Ball and Coulombe, 1991; Coulombe, 1993; Gallagher et al., 
1996).  Poultry, especially turkeys, are extremely sensitive to the toxic effects of 
AFB1 (Carnaghan et al., 1966; Arafa et al., 1981; Kubena et al., 1995; Klein et al., 
2000), a condition graphically demonstrated when this mycotoxin was 
discovered as the etiological agent of  “Turkey X Disease,” responsible for the 
deaths of poultry throughout Europe in the 1960s (Smith, 1960). We have 
previously shown that the extreme sensitivity of turkeys to AFB1 is associated 
 88 
with efficient hepatic microsomal bioactivation to exo-AFBO by homologues to 
human CYP1A2 and 3A4 (Klein et al., 2000; Yip and Coulombe, 2006; Chapter 2; 
Chapter 3). We recently cloned, expressed and characterized CYP1A5 (Yip and 
Coulombe, 2006) and 3A37 (Chapter 2; Chapter 3) from turkey liver, which, like 
the human homologues, produced exo-AFBO, and the detoxified metabolites 
AFM1 and AFQ1, respectively. Furthermore, the kinetics of exo-AFBO formation 
by CYP1A5 followed Michaelis-Menton kinetics, while those for 3A37 exhibited 
sigmoidal Hill‟s kinetics, suggestive of an allosteric interaction between AFB1 
and CYP3A37, showing positive cooperativity (Gallagher et al., 1996, Chapter 3). 
The relative roles of turkey CYP1A5 and 3A37 in the epoxidation of AFB1 is 
uncertain.  While the relative importance of human CYP1A2 and 3A4 in AFB1 
oxidation has been the subject of disagreement in the literature (Shimada and 
Guengerich, 1989; Ramsdell and Eaton, 1990; Ueng et al., 1995; Gallagher et al., 
1996), such studies have never been performed in turkeys. In the present study, 
we used antisera directed against CYP1A5 and 3A37 as tools to investigate the 
role of these enzymes in bioactivation of AFB1 in turkey liver microsomes 
(TLMs).  The purpose of this study was to evaluate which of these isoform is 
most active at relatively low concentrations of AFB1, more likely to be achievable 
in turkey liver, in vivo.  
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Material and Methods  
Chemicals, reagents, and antibodies. Rabbit polyclonal anti- CYP1A5 
(Yip and Coulombe, 2006) and 3A37 (Chapter 3) sera were raised against the 
peptide sequence “FLDFNKRFMKLLKTAVEE (amino acids 260-277)” and 
“SQKSDSDGKNSHKA (amino acids 278-291),” respectively (Genemed 
Synthesis, San Antonio, TX). These peptide sequences were selected by the 
manufacturer while taking into consideration that they should be antigenic, 
hydrophilic and readily accessible. Liver tissues were obtained from 1-day old 
male white turkeys, generously provided by Dr. Lynn Bagley, Moroni Feed Co. 
(Moroni, UT). All other chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO).      
Microsomal metabolism and determination of AFB1 metabolites. Turkey 
liver microsomes were prepared as previously described (Klein et al., 2002). The 
exo-AFBO intermediate is unstable and has a very short half-life, so it was 
determined indirectly as a stable, trapped AFBO-GSH conjugate using conditions 
described previously (Yip and Coulombe, 2006).  A reaction mixture consisting of 
turkey liver microsomes (~400 μg), butylated hydroxyl anisole (BHA)-induced 
mouse cytosol (~800 μg total protein) as a source of GST, 2mM NADPH, 5mM 
GSH and 0.1-1000 μM AFB1 in spectral grade dimethyl sulfoxide (DMSO) was 
made in epoxide trapping buffer (5 mM MgCl2, 25 mM KCl, 0.25 mM sucrose, 
and 80 mM potassium phosphate, pH 7.6) to give a final volume of 250 μL. The 
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reaction mixtures were incubated at 37ºC for 20 min with gentle shaking and 
stopped by adding 250 μL of cold methanol spiked with 24 μM aflatoxin G1 as an 
internal standard. The samples were kept overnight at -20 ºC to facilitate protein 
precipitation and then centrifuged at 13000Xg for 10 min. The supernatants were 
filtered through a 0.2 μm nylon membrane before 100 μL were injected into the 
HPLC. Metabolites were separated on a Shimadzu LC system (Shimadzu, 
Pleasanton, CA), equipped with a model LC-20AD pump, a model SPD-20AV 
UV-vis detector, and an Econosphere C18 (150 mm X 4.6 mm) column (Alltech 
Associates, Deerfield, IL) kept at 40ºC. The elution of the peaks was monitored 
by UV absorbance (λ=254 nm). The mobile phases used in this assay were as 
described previously (Klein et al., 2000).  Metabolite formation was quantified 
using curves between the peak areas in the chromatograms and the amounts of 
metabolites injected, using authentic AFBO-GSH, AFM1 and AFQ1 standards.  
Inhibition of microsomal CYP1A5 and 3A37 activities by anti-peptide 
antibodies. Anti-CYP1A5 or 3A37 immune serum (10 μg/ml/μg microsomal 
protein) or control preimmune serum ( 10 μg/ml/μg microsomal protein) were 
pre-incubated with the TLMs for 10 min at 4 ºC  before adding the other 
components of the epoxide trapping assay.   
Statistical analysis. Kinetic data were analyzed by SigmaPlot Enzyme 
Kinetics Module software (Systat Software, Inc., San Jose, CA). Data for 
CYP3A37 kinetics were analyzed by nonlinear regression using the Hill equation 
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to calculate Vmax and Km [V= Vmax [S]n/ ([Km]n + [S]n)]. In this equation, n 
represents the number of apparent binding sites. On the other hand, data for 
CYP1A5 kinetics were fit using the Michaelis-Menton equation [V= Vmax [S]/ (Km 
+ [S])].    
 
Results 
Metabolism of AFB1 by control TLMs. We used microsomes from the 
commercial birds, as they are shown to be more susceptible than the wild 
varieties (Quist et al., 2000). The differences may be due to the activity of GST, as 
P450 mediated oxidation of AFB1 from different varieties (wild, heritage and 
commercial) exhibited similar kinetics (data not shown). Oxidation of AFB1 to 
different metabolites was studied over concentrations ranging from 0.1-1000 µM 
using TLMs. Mean product formation rates from triplicate incubations were 
determined simultaneously at each substrate concentration in control 
(preimmune serum pretreated) microsomes and in the same microsomes 
pretreated with anti-CYP1A5 or 3A37 immune serum, to eliminate the 
contribution of CYP1A5 or 3A37 to product formation, respectively. AFB1 was 
metabolized to three products in control microsomes: exo-AFBO, AFM1 and 
AFQ1 in the ratio of (1: 0.53: 4.4). The V vs. S plot for the formation of these 
metabolites is shown in Figure 4.1. The kinetic parameters are presented in Table 
4.1. 
 92 
Metabolism of AFB1 by CYP3A37 (TLMs pretreated with anti-CYP1A5 
immune serum). In general, the formation of exo-AFBO and AFM1 was inhibited 
by pretreatment with anti-CYP1A5 immune serum, while AFQ1 formation was 
resistant to inhibition. Like the E. coli expressed CYP3A37, the rates of exo-AFBO 
and AFQ1 formation (in the ratio of 1: 6) followed sigmoidal Hill kinetics, 
indicative of positive cooperativity (Figure 4.2 and 4.3). The Eadie-Hofstee plots 
(Figure 4.2B for exo-AFBO, and 4.3B for AFQ1), indicated that 3A37 metabolism 
of AFB1 followed sigmoidal kinetics with a second order relationship between 
the substrate concentrations and product formation rates (Gallagher et al., 1996). 
While the Km values (Table 4.1) were similar to those of E. coli expressed 
CYP3A37 (exo-AFBO: 281 + 15 vs. 287 + 21 µM; AFQ1: 302 + 31 vs. 302 + 51 µM), 
Vmax values (Table 4.1) were smaller (exo-AFBO: 0.41 + 0.01 vs. 1.45 + 0.07 
nmol/min/nmol P450; AFQ1: 2.26 + 0.13 vs. 7.86 + 0.75 nmol/min/nmol P450) 
(Chapter 3). The apparent number of binding sites (“n”) was consistent to those 
in the E. coli expressed CYP3A37 (exo-AFBO: 1.9 + 0.14 vs. 1.9 ± 0.18; AFQ1: 1.6 + 
0.15 vs. 1.6 ± 0.26) (Chapter 3). AFM1 formation was inhibited by anti-CYP1A5 
immune serum at all AFB1 concentrations (data not shown). 
Metabolism of AFB1 by CYP1A5 (TLMs pretreated with anti-CYP3A37 
immune serum). The formation of exo-AFBO and AFQ1 were inhibited by 
pretreatment with anti-CYP3A37 immune serum, while AFM1 formation was 
relatively resistant to inhibition. Like the E. coli expressed turkey CYP1A5 (Yip 
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and Coulombe, 2006), formation of exo-AFBO and AFM1 (in the ratio of 1: 4) 
followed simple Michaelis-Menton kinetics (Figure 4.4 and 4.5).  The kinetic 
parameters listed in Table 4.1 show that Km values were similar to those of E. coli 
expressed CYP1A5 (exo-AFBO: 69 + 26 vs. 65 + 12 µM; AFM1: 37 + 6 vs. 34 + 9 
µM), while Vmax values were roughly 4-fold lower for AFM1 (0.28 + 0.01 vs. 0.91 + 
0.07 nmol/min/nmol P450) and more than 8-fold lower for exo-AFBO (0.07 + 
0.007 vs. 0.61 + 0.037 nmol/min/nmol P450) (Yip and Coulombe, 2006). AFQ1 
formation was inhibited by anti-CYP1A5 immune serum at all concentrations of 
substrate (data not shown). 
Metabolism of AFB1 in TLMs pretreated with both anti-CYP1A5 and 
3A37 immune serum. After inhibition of both the enzymes, no product 
formation was observed. 
Relative contribution of CYP1A5 and 3A37 in the epoxidation of AFB1 to 
exo-AFBO.  The inhibition of exo-AFBO formation in TLMs pretreated with anti-
CYP1A5 immune serum was most marked at low concentrations of AFB1, while 
pretreatment with anti-CYP3A37 immune serum resulted in marked inhibition of 
exo-AFBO at relatively high concentrations of AFB1 (Figure 4.6).  At 
submicromolar AFB1 concentrations (0.1 µM), CYP1A5 contributed about 98% to 
the total exo-AFBO formation (Figure 4.6). At the same concentrations, CYP1A5 
produced a higher ratio (50: 1) of activation to detoxification product (exo-AFBO: 
AFM1) compared to CYP3A37 (exo-AFBO: AFQ1 = 0.17: 1) (Table 4.2).       
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Discussion 
Previous studies in our laboratory have established that CYP1A5 and 
3A37, homologues to human CYP1A2 and 3A4, respectively, are the most 
important P450 isoforms responsible for the biotransformation of AFB1 in turkey 
liver (Klein et al., 2000; Yip and Coulombe, 2006; Chapter 3). Although both 
CYP1A5 and 3A37 epoxidate AFB1, their relative importance is uncertain because 
of several complicating factors: a) both enzymes produce activation (exo-AFBO) 
and detoxification products (AFM1 and AFQ1 by 1A5 and 3A37, respectively), b) 
the affinities of CYP1A5 and 3A37 toward AFB1 are substantially different (Yip 
and Coulombe, 2006; Chapter 3), and c) AFB1 metabolism by these enzymes 
conform to different kinetic models.  The relative importance of human CYP1A2 
and 3A4 with respect to AFB1 epoxidation have been the subject of conflicting 
reports mostly due to similar complications (Ramsdell and Eaton, 1990; Ueng et 
al., 1995; Gallagher et al., 1996; Kamdem et al., 2006). Indeed, there are striking 
similarities between human and turkey 1A and 3A homologues with respect to 
AFB1 metabolism in liver microsomal and heterologously-expressed systems 
(Gallagher et al., 1994, 1996; Yip and Coulombe, 2006; Chapter 3).  
In this study, we examined the kinetics of AFB1 oxidation by CYP1A5 and 
3A37 in TLMs, using anti-CYP1A5 and 3A37 immune serum as tools for 
sequentially isolating individual AFB1-metabolizing P450s for the purpose of 
identifying the predominant enzyme with particular attention to 
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environmentally-relevant or “real-world” concentrations seen in the livers of 
AFB1-exposed animals. 
When the contribution of CYP3A37 was eliminated by immunoinhibition, 
TLMs oxidized AFB1 to just two products, exo-AFBO and AFM1, characterized by 
hyperbolic Michaelis-Menton kinetics. Identical characteristics have been 
observed in E. coli expressed CYP1A5 (Yip and Coulombe, 2006) and human 
CYP1A2 (Gallagher et al., 1996). Conversely, when CYP1A5 was 
immunoinhibited, TLMs produced exo-AFBO and AFQ1, best fitting sigmoidal 
Hill kinetics in agreement with the previous reports for CYPs 3A4 and 3A37 
(Gallagher et al., 1996; Chapter 3). Examination of the Hill equation parameters 
suggested that, while the affinity of CYP3A37 for AFB1 is less than that of 
CYP1A5, its maximal velocity is about 6-times greater.  
The sigmoidal relationship observed between the substrate concentrations 
and the rates of product formation, suggests that CYP3A37 interacts with AFB1 in 
an allosteric manner, indicative of positive cooperativity. Similar sigmoidal 
behavior for P450 3A in other species have been observed. Using 7-benzyloxy-4-
(trifluoromethyl)-coumarin (BFC) and nonylphenol as CYP3A substrates, both 
homotropic and heterotropic cooperative interactions were described in fish 
(Kullman et al., 2004). Furthermore, human CYP3A4-catalyzed, oxidation of AFB1 
to AFBO and AFQ1, and formation of temazepam from diazepam showed 
allosterism, with the data fitting well to sigmoidal Vmax model equivalent to the 
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Hill equation (Andersson et al., 1994; Gallagher et al., 1996). In addition, 
Gallagher et al (1996) observed sigmoidal kinetics for the formation of AFBO and 
AFQ1 in human liver microsomes pretreated with furafylline, a mechanism based 
inhibitor of CYP1A2. Several models have been proposed for the cooperativity 
observed with CYP3A4 homologues, indicating the presence of a distinct 
allosteric site, where binding of an effector or substrate molecule enhances 
binding of substrate at the active site and involves a change in the conformation 
of the active site (Ueng et al., 1997; Davydov and Halpert, 2008). 
This atypical sigmoidal second-order kinetics associated with CYP3A37 
and AFB1 implies that the rate of product formation falls off steeply at low 
substrate concentrations (Gallagher et al., 1996).  However, such is not the case 
for CYP1A5 which follows first order hyperbolic Michaelis-Menton kinetics 
(Gallagher et al., 1996). Our results clearly show that at lower AFB1 
concentrations, such as at 0.1 µM, nearly all exo-AFBO is formed by CYP1A5 
(Table 4.2).  Residual AFB1 and stable detoxified metabolites in the livers of 
chickens and other domesticated fowl were in the range of 0.15-7.83 and 1.54-
22.34 ppb, respectively, after an 8-day exposure to a diet containing containing 3 
ppm AFB1 (Bintvihok et al., 2002).  The higher range (~0.025-0.072 µM) of these in 
vivo concentrations of AFB1 and of its metabolites is very close to 0.1 µM used in 
our assays.  While in vitro metabolic systems only provide an approximation of 
the hepatic milieu in vivo, it seems reasonable to conclude that the formation of 
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exo-AFBO, as well as the disposition of AFB1, at “real world” concentrations is 
probably dominated by CYP1A5.  The probability that the in vivo concentration 
of AFB1 at the site of the P450 enzyme would actually exceed those used in in 
vitro assay is very low; AFB1 needs to traverse the lipid membranes in order to 
distribute and the total fraction of lipid at in vivo conditions would probably be 
much higher than those of in vitro microsomal fraction (Gallagher et al., 1996).  
Our data shows that, at 0.1 µM AFB1 concentrations, CYP1A5 produced a 
much higher ratio (50: 1) of activation (exo-AFBO) to detoxification product 
(AFM1), relative to CYP3A37. In addition, the ratio of activation: inactivation 
products formed in TLMs also suggests relatively higher contribution of CYP1A5 
to the AFB1 activation as compared to CYP3A37. Previous studies examining the 
kinetics of AFB1 oxidation by E. coli expressed CYP1A5 and 3A37 in our 
laboratory also indicates similar findings; CYP1A5 produced exo-AFBO and 
AFM1 (AFB1 concentrations: 2 - 500 µM) in a ratio of 1: 2, while CYP3A37 
produced exo-AFBO and AFQ1 (AFB1 concentrations: 0.1 - 1000 µM) in a ratio of 
1: 6 (Yip and Coulombe, 2006; Chapter 3). The ratios of activation: inactivation 
products catalyzed by CYP1A5 and 3A37 are likely to be an important factor in 
the biological consequences of in vivo AFB1 exposure in turkeys. While CYP3A 
activity is higher than that of 1A in the turkey liver (Guarisco et al., 2008), the 
apparent low affinity of 3A37 at submicromolar liver AFB1 concentrations, makes 
it highly unlikely that this enzyme would bioactivate AFB1 substantially in vivo. 
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At 0.1 µM AFB1 concentrations, the ratio of the contributions of CYP1A5: 3A37 to 
the formation of exo-AFBO is 98: 2.   
Based on our results, inhibition of CYP1A5 may significantly alleviate the 
symptoms of aflatoxicosis in poultry exposed to dietary AFB1. In fact, butylated 
hydroxytoulene (BHT) added to turkey feed provided improvements in the 
AFB1-associated symptoms in turkeys, in part, due to its inhibitory effect on 
CYP1A5, exhibiting Michaelis-Menton competitive inhibition kinetics (Ki=0.81 
µM) (Guarisco et al., 2008). Guarisco et al. (2008) also showed that BHT induces 
CYP3A, which implies that this enzyme is probably not bioactivating AFB1 in 
vivo; rather it may be contributing to the protective effects of BHT by possible 
detoxification to AFQ1. In conclusion, our in vitro kinetic studies of AFB1 
oxidation indicate that the dominant catalyst of AFB1 epoxidation at in vivo 
dietary concentrations obtained in turkey liver is CYP1A5.   
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  Table 4.1. Kinetic constants of CYP1A5 and 3A37 catalyzed AFB1 (0.1-1000 μM) 
metabolism in control, and immunoinhibited turkey liver microsomes.1,2,3  
 
   
1Microsomes were pretreated with anti-CYP1A5 or 3A37 immune serum (10 
μg/ml/μg microsomal protein) for 10 min   
2Vmax is expressed in nmol/min/nmol P450, Km in µM, N is the number of 
apparent binding sites 
3Data are mean + SE (n=3) 
4ND: Not Detected  
 
 
 
 
Metabolite Kinetic 
constants 
Control  
 
+ Anti-CYP1A5  + Anti-CYP3A37  
exo-AFBO Vmax 
Km 
N 
0.47 + 0.03 
266 + 32 
1.7 + 0.20 
0.41 + 0.01 
281 + 15 
1.9 + 0.14 
0.07 + 0.007 
69 + 26 
- 
AFQ1 Vmax 
Km 
N 
2.07 + 0.13 
305 + 33 
1.7 + 0.18 
2.26 + 0.13 
302 + 31 
1.6 + 0.15 
ND4 
ND 
ND 
AFM1 Vmax 
Km 
N 
0.25 + 0.009 
41 + 6 
- 
ND 
ND 
- 
0.28 + 0.01 
37 + 6 
- 
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Table 4.2. Relative contribution of CYP1A5 and 3A37 to the activation (exo-
AFBO) vs. inactivation (AFM1 and AFQ1) products formed in control and 
immunoinhibited TLMs, at 0.1 µM AFB1, which are close to those potentially 
encountered via real world dietary exposure. 
1All values are pmol/min/nmol P450.   
2ND: Not detected 
   
 
 
 
 
 
 
 
 
 
 
 
 
Metabolite Control 
(Preimmune serum) 
CYP1A5 (anti-CYP3A37 
immune serum) 
CYP3A37 (anti-CYP1A5 
immune serum) 
exo-AFBO1 18.8 18.5 0.19 
AFM11 0.3 0.37 ND2 
AFQ11 1.06 ND 1.23 
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Figure 4.1. Kinetics of AFB1 metabolism in control TLMs (pretreated with 
preimmune serum). Three metabolites were produced: exo-AFBO, AFM1 and 
AFQ1, a metabolic profile indicative of functioning microsomal CYP1A5 and 
3A37. Points are mean + SE (n = 3).  
 
 
 
 
 
 
 
 
 104 
 
 
Figure 4.2. The rates of exo-AFBO formation in TLMs pretreated with anti-
CYP1A5 immune serum (10 μg/ml/μg microsomal protein).  The resultant exo-
AFBO formation showed sigmoidal Hill‟s kinetics, typical of CYP3A37. (A) V vs. 
S plot of exo-AFBO formation. (B) Eadie- Hofstee plot of exo-AFBO formation.  
Points are mean + SE (n = 3).  
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Figure 4.3. The rates of AFQ1 formation in TLMs were not attenuated by 
pretreatment with anti-CYP1A5 immune serum.  AFQ1 formation which is 
exclusively by CYP3A37 followed sigmoidal Hill‟s kinetics. (A) V vs. S plot of 
AFQ1 formation.  (B) Eadie- Hofstee plot of AFQ1 formation.  Points are mean + 
SE (n = 3).  
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Figure 4.4. The rates of exo-AFBO formation in TLMs pretreated with anti-
CYP3A37 immune serum (10 μg/ml/μg microsomal protein).  After attenuation 
of CYP3A37, exo-AFBO formation showed Michaelis-Menton kinetics, typical of 
CYP1A5. The data were therefore were analyzed by fitting into Michaelis-
Menton equation. Points are mean + SE (n = 3).  
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Figure 4.5. The rates of AFM1 formation in TLMs were not attenuated by 
pretreatment with anti-CYP3A37 immune serum.  AFM1 formation which is 
exclusively by CYP1A5 followed simple Michaelis-Menton kinetics. Points are 
mean + SE (n = 3).  
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Figure 4.6. The relative contribution of CYP1A5 and 3A37 on AFB1 epoxidation 
can be seen by the differential effects of anti-CYP1A5 and 3A37 immune serum 
(10 μg/ml/μg microsomal protein) on the initial rates of exo-AFBO formation in 
TLMs.  Rates of exo-AFBO formation in the presence of antiserum were 
calculated as percentage control (treatment with preimmune serum only). Each 
bar is mean + SD. (n = 3). 
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CHAPTER 5 
CHEMOPREVENTION OF AFLATOXICOSIS BY PROBIOTC 
LACTOBACILLUS IN TURKEYS 
Abstract 
Aflatoxin B1 (AFB1), a well-known human carcinogen, is a mycotoxin 
produced as secondary metabolite by the fungi Aspergillus flavus, A. parasiticus, 
and A. nominus. Poultry, specifically turkeys, are extremely sensitive to the toxic 
effects of AFB1, which makes them an excellent model to study AFB1 
chemopreventives. Probiotic bacteria are able to bind AFB1 and reduce its 
bioavailability. Combinations of different probiotic bacteria are often used by the 
food industry as biopreservatives, making them a suitable candidate to study for 
chemopreventive actions. This study aims to investigate the protective action of 
probiotic Lactobacillus: consisting of Lactobacillus rhamnosus strains GG and LC-
705, Propionibacterium freundenreichii sp shermani and Bifidobacterium sp (LGG), 
on AFB1 toxicosis in turkeys. Day-old turkeys were chosen for this study and the 
trial lasted for 21 days. After acclimatization for 10 days, birds were placed in 
one of the four groups (n=10): LGG, LGG+AFB1, Control, and AFB1. Birds were 
pretreated daily with 0.5 ml of either  LGG (5 X 1010 cfu/0.5 ml PBS, prepared by 
directly suspending lyophilized bacteria in PBS) (groups: LGG and LGG+AFB1) 
or PBS (groups: Control and AFB1), by oral gavage for the first 10 days, before 
starting AFB1 treatment at 1 ppm in the diet. Birds received LGG, PBS and AFB1 
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for the rest of the period of the trial depending upon the group assignment. LGG 
+ AFB1-treated group showed significantly higher body and liver weights than 
those treated with AFB1-alone. Serum profile, histopathological and AFB1-lysine 
adduct data supports the protective role of LGG, however the differences were 
not statistically significant. In conclusion, our results indicate that LGG provides 
protection against some of the deleterious effects of AFB1 and that this probiotic 
may prove to be a viable chemopreventive for aflatoxicosis in turkeys.     
Introduction 
Aflatoxins, produced as secondary metabolites of the fungi Aspergillus 
flavus, A. parasiticus, and A. nominus, are classified human carcinogens (Bondy 
and Pestka, 2000). Of all aflatoxins, AFB1 is the most toxic, causing growth 
impairment and immunosuppresion in a range of domesticated animals and 
livestock (Richard et al., 1986; Coulombe, 1993).  The toxicity of AFB1 is 
dependent on the formation of exo-AFB1-8,9-epoxide (AFBO) by cytochromes 
P450 (CYP for gene; P450 for protein), which is electrophilic, and binds to DNA, 
RNA and other critical cellular nucleophiles to cause cellular toxicosis, 
mutagenesis and carcinogenesis (Ball and Coulombe, 1991; Coulombe, 1993; 
Gallagher et al., 1996; Guengerich et al., 1996). Glutathione-S-Transferases (GST) 
are able to detoxify the AFBO, by conjugating it with endogenous glutathione. 
This detoxification mechanism is critical in determining the susceptibility of a 
species to AFB1 toxicosis (Coulombe, 1993). Poultry, specifically turkeys, are 
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extremely sensitive to the toxic effects of AFB1 (Carnaghan et al., 1966; Arafa et 
al., 1981; Giambrone et al., 1985; Huff et al., 1986; Kubena et al., 1995; Klein et al., 
2000). Sensitivity of turkeys to AFB1 was first demonstrated by their association 
with the “Turkey X Disease” which caused widespread deaths of turkeys and 
other poultry throughout Europe in the 1960s (Stevens et al., 1960). We 
previously established that this extreme sensitivity of turkeys to AFB1 is in part, 
due to an unfortunate combination of efficient epoxidation by P450s and 
deficient detoxification by GSTs (Klein et al., 2000; Yip and Coulombe, 2006; 
Chapter 2). Aflatoxin B1 in turkey feed results in poor performance, decreased 
body and organ weights, immunosuppression, morbidity, and mortality (Kubena 
et al., 1990, 1991; Coulombe, 1993). According to a report by Council for 
Agricultural Science and Technology, losses due to aflatoxins to US poultry 
industry exceeded $143 million annually (CAST, 1989). A recent study reported 
annual crop losses of $932 million due to mycotoxin contamination and 
additional losses of $466 million in efforts to prevent or reduce contamination 
(CAST, 2003). Given that AFB1 contamination in feed is nearly universal, and 
therefore practically unavoidable (Coulombe et al., 2005), chemoprevention 
strategies aimed at reducing AFB1 toxicity in poultry and other animals have 
been the subject of numerous studies (Klein et al., 2002b, 2003; Guarisco et al., 
2008a, 2008b). Indeed, because of their sensitivity, poultry have been used as 
models for discovery of novel AFB1 chemopreventives.   Our laboratory recently 
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studied AFB1 chemoprevention by the antioxidant butylated hydroxytoluene 
(BHT). The protective properties of BHT appeared to be due to an inhibitory 
effect on the activity of P450 1A1 and 1A2, suggesting reduced bioactivation of 
AFB1 to the AFBO (Klein et al., 2003). Further studies revealed that dietary BHT 
reduced AFBO formation, as well as other CYP1A5-mediated activities (Guarisco 
et al., 2008b). Furthermore, dietary BHT caused significant reductions in AFB1 
bioavailability, AFB1–DNA adduct formation in the liver, and reduced AFB1 
residues in tissues (Guarisco et al., 2008a).  
Probiotic bacteria, such as Lactobacillus rhamnosus, bind to AFB1, and play 
a protective role in humans (Wollowski et al., 2001). Because of its use in various 
dairy products, including yogurt, L. rhamnosus is therefore considered a good 
candidate for evaluating its AFB1 chemopreventive potential in turkeys. 
Lactobacillus rhamnosus strains GG and LC-705 were found to be the most efficient 
in binding a range of mycotoxins including aflatoxins (El-Nezami et al., 1998, 
2002a, 2002b; Haskard et al., 2001; Peltonen et al., 2001). In addition, L. rhamnosus 
reduced AFB1 transport, metabolism, and toxicity in Caco-2 cells (Gratz et al., 
2007). Furthermore, L. rhamnosus reduced the AFB1 bioavailability in rats, thereby 
decreasing its toxicity (Gratz et al., 2006). Thus, there exists substantial evidence 
of the protective role of probiotics in preventing aflatoxicosis. The present study 
aims to evaluate the chemopreventive action of LGG on AFB1 toxicity in turkeys, 
a species extremely susceptible to aflatoxicosis.   
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Material and Methods 
Bacterial strains. A freeze-dried mixture of probiotics, “LGG” (Valio Ltd., 
Helsinki, Finland), consisting of Lactobacillus rhamnosus GG (2.3 X 1010 cfu/g), 
Lactobacillus rhamnosus LC-705 (3.0 X 1010 cfu/g), Propionibacterium freundenreichii 
sp shermani (3.5 X 1010 cfu/g), and Bifidobacterium sp (2.9 X 1010 cfu/g) was 
generously provided by Dr. Hani El-Nezami, University of Kuopio (Kuopio, 
Finland). Additionaly, this mixture contained 58% microcrystalline cellulose, 
27% gelatin, and magnesium stearate. LGG was administered to turkeys by oral 
gavage in final concentrations of 5 X 1010 CFU/0.5 ml phosphate buffered saline 
(PBS), prepared by directly suspending lyophilized bacteria in PBS (Gratz et al., 
2006).  
Animals and Treatment. Animals were cared for under institutional 
approval in an AAALAC-accredited facility. The Utah State University Animal 
Care and Use Committee approved all procedures involving animal care, 
euthanasia and tissue collection. Turkeys and feed were generously provided by 
Moroni Feed Co. (Ephraim, UT). One day-old male Nicholas strain turkeys were 
used for this study because previous studies indicate that younger birds are 
more susceptible to aflatoxicosis than older ones (Klein et al., 2002a). Birds were 
maintained on a corn-based commercial starter diet for the duration of the trial, 
which lasted 21 days. After acclimatization for 10 days, birds were randomly 
placed in one of the four groups (n=10): LGG, LGG + AFB1, Control, and AFB1. 
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For the first 10 days, birds placed in LGG and LGG + AFB1 groups received 
pretreatment with 0.5 ml of LGG  and those placed in Control and AFB1 groups 
received pretreatment with PBS (0.5 ml), once daily, by oral gavage, after which 
AFB1 treatment (for groups: LGG + AFB1 and AFB1) was started at 1 ppm in the 
diet. Aflatoxin B1 and LGG or PBS treatment continued for the next 11 days.  
Thereafter, animals were euthanized by CO2 asphyxiation. Blood was collected 
by cardiac puncture in sterile, no-additive tubes (Becton Dickinson Vacutainer®, 
Franklin Lakes, NJ) for serum and in heparinized tubes for plasma collection, 
and livers were rapidly removed and frozen on dry ice. The plasma and serum 
were removed within 1 h of blood collection. Livers were sectioned for 
histological analysis as described below, prior to freezing. The collected serum, 
plasma and tissues were stored at − 80 °C until analyzed. Small sections of 
spleens were cut and stored in RNA later (Ambion Inc., Austin, TX) solution for 
cytokine gene expression analysis. Turkeys were weighed on day 1, 8, 15, 19 and 
before euthanasia on day 21 and livers were weighed when sampled on day 21st.   
Histological analysis. Liver sections were fixed in neutral buffered 10% 
formalin immediately upon removal. A section of each liver was embedded in 
paraffin using a Model TP1050 Embedding Station (Leica Microsystems, 
Deerfield, IL), thin sectioned (RM 2145 Microtome, Leica Microsystems), and 
stained with hematoxylin and eosin (H&E) (Jung Autostainer XL, Leica 
Microsystems). Tissues were then fixed to the slides for histological analysis. 
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Each slide was evaluated for hepatic necrosis and biliary hyperplasia. A 
numerical score of 1 to 5 for the severity was assigned to each sample as follows 
(Klein et al., 2002b): hepatocellular necrosis, based on percent of viewed cells 
affected, 1 =< 5%, 2 = > 5 to 30%, 3 = > 30 to 60%, 4 = > 60 to 80%, or 5 = > 80%; 
biliary hyperplasia, 1 = normal, 2 = mild proliferation without parenchymal 
displacement, 3 = moderate proliferation with some mild parenchymal 
displacement, 4 = moderate to severe proliferation with moderate parenchymal 
displacement, or 5 = diffuse proliferation with severe parenchymal displacement.   
Cytokine gene expression analysis. RNA was extracted from RNA later 
stored spleens, using an RNeasy Mini Kit (Qiagen).  cDNA was transcribed using 
a high capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Quantitative real-time PCR was performed on an Applied Biosystems 7500 Fast 
machine using Fast SYBR Green (Applied Biosystems).  The run conditions were 
as follows: 20 seconds of initial denaturation at 95°C, 40 cycles of denaturation at 
95°C at 3 seconds each, and 30 seconds of annealing and extension at 60°C. 
Aflatoxin-lysine (AFB1-lys) adducts analysis. Samples were analyzed for 
AFB1-lys by Liquid chromatography-Mass Spectrometry (LC/MS/MS) by a 
modified method as described previously (McCoy et al., 2005). This method 
involves digestion and isolation of AFB1 adducts, but only measures AFB1-lys. 
AFB1-lys residues previously separated by LC were MS fragmented. 
Quantification used authentic standards. 
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Statistical analysis. Groups were compared, for differences, using 
appropriate ANOVA models and post-hoc tests as described under results. A 
level of p < 0.05 was chosen as statistically significant.  
Results 
Mean body weights for each treatment group over the course of the trial 
are summarized in Figure 5.1. LGG exerted a strong protective effect against 
primary endpoints of aflatoxicosis, like percent body weight gains, which were 
analyzed by a two-way factorial ANOVA model with main factors treatment 
(LGG treatment or not) and diet (AFB1 or not) using proc mixed in SAS (Cary, 
NC). LGG-treated birds had significantly higher weight gains as compared to 
those which did not receive this treatment, with an estimated difference of about 
83 % (p-value < 0.0001). As anticipated, birds receiving non-AFB1 diets, had 
significantly higher weight gains than those which received AFB1 in their diet, 
with an estimated difference of about 52 % (p-value = 0.0005). Percent body 
weight gain on day 21 relative to day 1 shows that, AFB1-alone group 
experienced a significantly lower weight gain as compared to other groups 
(Figure 5.2) (p-values adjusted for multiple comparison were all 0.0002 or less), 
while the pairwise differences amongst groups LGG, LGG + AFB1 and Control 
were not significant (smallest adjusted p-value for between-group comparison 
was 0.10, for LGG vs. Control). While AFB1-alone group experienced about 350% 
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body weight gain, LGG, LGG +AFB1 and Control groups experienced, on an 
average over 440% (Figure 5.2).  
Protective effects of LGG were also seen when liver weight was 
considered. Summary of liver and body weights and liver: body weight ratios on 
the day of sampling (day 21) are shown in Table 5.1. Similar to the ANOVA 
model for percent body weight gain, an ANOVA model was fit to the liver 
weight data.  Model diagnostics identified the lowest liver weight in one of the 
birds in the LGG +AFB1-group as an outlier, so that bird was dropped from the 
liver weight analysis.  From this model, birds receiving the non-AFB1 diet had 
significantly higher liver weights than those with AFB1 in diet (estimated 
difference 3.2g, p-value < 0.0001).  There was no significant liver weight 
difference due to LGG treatment.  There was no significant difference between 
the  liver weights means amongst  LGG, LGG + AFB1 and Control groups 
(smallest adjusted p-value for between-group comparison is 0.15, for LGG + 
AFB1 vs. Control), while even after adjusting for multiple comparisons, AFB1-
alone group liver weight was significantly lower than LGG (estimated difference 
4.20g, p-value=0.0003), LGG + AFB1 (estimated difference 2.97g, p-value=0.02), 
and Control (estimated difference 5.16g, p-value < 0.0001) groups. Groups fed 
AFB1 diet had significantly lower liver : body weight ratios than those receiving 
non-AFB1 diets. 
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The principal target organ of AFB1 toxicosis is the liver. To assess the 
degree of hepatic damage, serum profiles were analyzed (Figure 5.3). Serum data 
were analyzed for within group differences using one-way ANOVA model with 
a post-hoc Tukey test.  Serum gamma-glutamyltransferase (GGT) was 
significantly elevated in AFB1-treated groups as compared to the groups fed non-
AFB1 diet. The mean level of GGT was slightly lower, but not significantly 
different; in LGG + AFB1-group as compared to those of AFB1-alone group (12.8 
+ 1.6 versus 12.6 + 5.7 U/L). Both total protein and albumin were significantly 
lower in AFB1-treated groups as compared to the non-AFB1 groups. Serum 
alkaline phosphatase, however, was significantly elevated in groups fed non-
AFB1 diet than those in AFB1-treated animals. There was no statistically 
significant trend associated with AST, ALT, and bilirubin values (data not 
shown).  
After the birds were sacrificed, their livers were grossly examined for 
hepatic changes, such as hemorrhaging, tissue firmness and color changes. 
Visual examination showed that livers from AFB1-alone groups were pale and 
firm, whereas these changes were reduced in LGG + AFB1-treated group and 
completely absent in groups fed non-AFB1 diet. Histology of liver sections 
revealed hepatic necrosis and biliary hyperplasia in AFB1- treated birds (Table 
5.2), which were absent in control birds. Hepatic necrosis was mildly reduced in 
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turkeys treated with LGG + AFB1 as compared to AFB1-alone group, but the 
differences were not statistically significant. 
The relative gene expression of proinflammatory cytokines IL-8 and IL-1β, 
and anti-inflammatory cytokines IL-10 and IL-6 was analyzed by real-time PCR, 
using GAPDH as the endogenous control. AFB1-alone group showed 
upregulation of IL-1β and IL-10, and downregulation of IL-8 and IL-6, as 
compared to those of LGG + AFB1-group (Figure 5.4). Results were highly 
variable and there was no statistically significant trend associated with any of the 
cytokines. 
Mean amounts of AFB1-lys adducts in the plasma were lower in 
LGG+AFB1-treated group than those in AFB1-alone group, though the difference 
was not statistically significant (1773 ± 215.9 versus 2169 ± 194.5 pg/mg) (Figure 
5.5). These adducts were not detected in the birds fed non-AFB1 diet. Visual 
inspection over the course of the trial indicated that birds which received LGG, 
were in general more active.  
Discussion  
Previous results from our laboratory has established that the extreme 
sensitivity of turkeys to AFB1 is due, in part, to efficient P450 mediated 
bioactivation and deficient detoxification by GSTs (Klein et al., 2000; Yip and 
Coulombe, 2006; Chapter 2). Given that AFB1 is an unavoidable contaminant of 
poultry feed (Coulombe et al., 2005), chemopreventive measures aimed to reduce 
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the toxicity of AFB1 have been a subject of intense research. Here, we report the 
protective role of LGG against some end points of aflatoxicosis in turkeys. 
Probiotics have been previously shown to bind AFB1 and subsequently reduce its 
toxicity in-vivo in rats and in-vitro in cultured Caco-2 cells (Gratz et al., 2006, 
2007). To our knowledge, this has not been reported for turkeys thus far.  
The beneficial effects of orally administered LGG were observed in key 
endpoints of aflatoxicosis. First, reduction in body weight gain due to AFB1 
returned to control values by LGG treatment, which was presumably due to the 
binding of AFB1 by LGG leading to its excretion (Gratz et al., 2006). Turkeys are 
an agriculturally important production animal in the United States, thus weight 
gain is of critical economic importance and must be taken into consideration in 
the evaluation of any chemopreventive. Protective effects of LGG on AFB1-
induced weight loss were seen in rats (Gratz et al., 2006). Similar protective 
binding of AFB1 by strains of Lactobacillus and Propionibacterium was seen in 
chickens (El-Nezami et al., 2000).  
Although AFB1 generally affects most systems, liver is the principal organ 
of effect for AFB1 toxicosis. Aflatoxin B1 has been shown to reduce the relative 
liver weights in turkeys (Klein et al., 2002b; Kubena et al., 1995). LGG provided 
amelioration in the AFB1-associated reduction in liver weights in turkeys. Serum 
enzyme and histopathological data showed protection, but the differences were 
not significant. These findings are potentially suggestive of increased retention of 
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aflatoxin by LGG in the gastrointestinal tract of turkeys, which may consequently 
reduce the toxicity of a high AFB1 exposure. 
Aflatoxins are immunosuppresive in poultry, in part, through their effects 
on cytokines (Qureshi et al., 1998; Yarru et al., 2009). Our results indicate 
downregulation of anti-inflammatory cytokine, IL-6, in AFB1-alone group, which 
was consistent with earlier reports (Yarru et al., 2009). AFB1-induced alteration of 
cytokine expression among species appears to be highly variable (Rossano et al., 
1999; Liu et al., 2002). Although the gene expression of cytokines was not 
significantly altered due to LGG treatment, our results provide an additional 
evidence for a species-dependent immune response to AFB1.  
Treatment with LGG lowered, but did not alter the AFB1-lys adduct 
amounts significantly. Similar findings were reported by Gratz et al. (2006), 
suggesting a saturation of the hepatic metabolizing capacity within the dosing 
regimen used. 
Thus, LGG provided some evidence of its protective effects in AFB1-
associated toxicity in turkeys. Several strains of probiotic bacteria are known to 
bind a range of mycotoxins including aflatoxins. Of these strains, Lactobacillus 
rhamnosus strain GG and LC-705 appears to be most efficient in binding AFB1 to 
the bacterial surface (El-Nezami et al., 1998, 2002a, 2002b; Haskard et al., 2001). In 
conclusion, LGG provides protection against AFB1-induced reduction in body 
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and liver weights in turkeys, however chronic studies are required to evaluate its 
potential role as a possible chemopreventive against aflatoxicosis in turkeys. 
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Table 5.1. The effect of orally administered LGG on liver, body, and liver to body 
weight ratio in turkeys on the day (21st) of sampling1.  
1Male turkeys were placed in one of the four groups: LGG, LGG+AFB1, Control, 
and AFB1. After 10 days of pretreatment with either LGG (groups: LGG and 
LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to the 
diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the next 
11 days, depending upon the group assignment.  
2Values are mean (+ SD) n = at least 9. Different superscripts indicate significant 
differences among groups (p < 0.05).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Liver Weight2 Body Weight2 Liver/body weight 
ratio2 
LGG 19.23 (1.91)a   854.11 (83.05)a,c 0.03 (0.002)a 
LGG+AFB1 18.00 (2.18)a 901.15 (94.97)a,c 0.02 (0.001)b 
Control 20.19 (2.98)a 825.79 (129.44)b,c 0.03 (0.002)a 
AFB1 15.03 (0.98)b 738.71 (60.55)b 0.02 (0.001)b  
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Table 5.2. Histopathologic lesion severity scoring of turkeys in different groups1.  
1Male turkeys were placed in one of the four groups: LGG, LGG+AFB1, Control, 
and AFB1. After 10 days of pretreatment with either LGG (groups: LGG and 
LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to the 
diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the next 
11 days, depending upon the group assignment.  
2Values are mean (+ SD) n = atleast 9. Different superscripts indicate a significant 
difference among groups (p < 0.05). 
  
  
  
 
 
 
 
 
 
 
 
 
 
Treatment Biliary Hyperplasia2 Hepatic Necrosis2 
LGG 1.00 (0.00)a 1.10 (0.31)a 
LGG+AFB1 3.33 (1.12)b  2.00 (0.50)b 
Control 1.00 (0.00)a 1.00 (0.00)a 
AFB1 3.09 (0.94)b 2.18 (0.40)b  
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Figure 5.1. The protective effect of orally administered LGG on AFB1-induced 
declines in mean body weights in turkeys over the course of the study. On day 1, 
LGG, LGG + AFB1 and Control groups had 10 birds each, while AFB1-alone 
group had 11. One bird in LGG + AFB1 died on day 3rd after the start and no 
other mortalities were seen during the course of the trial.  
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Figure 5.2. The chemopreventive effect of orally administered LGG on AFB1-
induced reduction in percent body weight gain (on day 21 relative to day 1) in 
turkeys. AFB1-alone group had significantly lower weight gain than rest of the 
groups. Male turkeys were placed in one of the four groups: LGG, LGG+AFB1, 
Control, and AFB1. After 10 days of pretreatment with either LGG (groups: LGG 
and LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to 
the diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the 
next 11 days, depending upon the group assignment. Each box represents the 
mean + SD (n = atleast 9). Different superscripts indicate significant difference 
among groups (p<0.05) (n = at least 9). 
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Figure 5.3. The effect of orally administered LGG on serum chemistries in 
turkeys. Male turkeys were placed in one of the four groups: LGG, LGG+AFB1, 
Control, and AFB1. After 10 days of pretreatment with either LGG (groups: LGG 
and LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to 
the diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the 
next 11 days, depending upon the group assignment. (A) ALP, (B) GGT, (C) 
Total protein, (D) Total albumin. Each bar represents the mean + SD (n = at least 
9). Different superscripts indicate a significant difference among groups (p < 
0.05).  
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Figure 5.4. The effect of orally administered LGG on Relative Quantification of 
cytokines as assessed by RT-PCR in turkeys. Male turkeys were placed in one of 
the four groups: LGG, LGG+AFB1, Control, and AFB1. After 10 days of 
pretreatment with either LGG (groups: LGG and LGG+AFB1) or PBS (groups: 
Control and AFB1), 1 ppm AFB1 was added to the diets of two AFB1-treated 
groups. Birds received LGG, PBS and AFB1 for the next 11 days, depending upon 
the group assignment. 
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Figure 5.5. The effect of orally administered LGG on AFB1-lys adducts in turkeys. 
AFB1-lys adducts were detected in plasma of groups receiving AFB1 in diet and 
were absent in those receiving AFB1-free diet. Male turkeys were placed in one of 
the four groups: LGG, LGG+AFB1, Control, and AFB1. After 10 days of 
pretreatment with either LGG (groups: LGG and LGG+AFB1) or PBS (groups: 
Control and AFB1), 1 ppm AFB1 was added to the diets of two AFB1-treated 
groups. Birds received LGG, PBS and AFB1 for the next 11 days, depending upon 
the group assignment. Each bar represents the mean + SD (n = at least 9).  
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CHAPTER 6 
SUMMARY AND FUTURE WORK  
Extreme sensitivity of turkeys to AFB1 is explained in part, by the 
presence of efficient epoxidating P450 1A and 3A homologues. This research 
project aimed to identify and characterize these P450s in turkeys. Further 
research focused on determining the relative importance of P450 1A5 and 3A37 
in AFB1 epoxidation and to elucidate the detailed metabolism of AFB1 in turkey 
liver microsomes. In another task, the chemopreventive action of probiotic 
bacteria, Lactobacillus, was studied on AFB1 toxicity in turkeys. Because of their 
extreme sensitivity, turkeys make an excellent model to study AFB1 
chemopreventives.  
 The results of this study identified a CYP3A4 homologue, CYP3A37, from 
the turkey liver. The gene for this P450 was found to have an ORF of 1512 bp, 
and the protein was predicted to be 504 amino acids with 97% identity to chicken 
CYP3A37. Our results demonstrates the utility of deletion of hydrophobic N-
terminal nucleotide sequences (5‟ – end) to enhance the expression of P450s in E. 
coli. The N-terminal truncated CYP3A37 expressed in E. coli produced substantial 
amounts of active P450 to support the catalytic activities. The sequence of 
CYP3A37 was 66% identical to human CYP3A4 and the catalytic activities of the 
E. coli expressed protein closely resembled that of its human counterpart. For 
example, CYP3A37 biotransformed AFB1 to exo-AFBO and AFQ1 and possessed 
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nifedipine oxidase activity, both of which were inhibited by CYP3A4 inhibitor 
17α-ethynylestradiol. Like the human CYP3A4, the kinetics of the oxidation of 
AFB1 to exo-AFBO and AFQ1 by CYP3A37 conformed to sigmoidal Hill kinetics, 
suggesting that there be an allosteric interaction between AFB1 and CYP3A37, 
indicative of positive cooperativity. Of particular importance was the metabolism 
of AFB1 by the E. coli expressed protein of CYP3A37 to exo-AFBO. Exo-AFBO, a 
highly reactive electrophilic intermediate, is responsible for the carcinogenic and 
mutagenic effects of AFB1. Thus, we concluded that CYP3A37 along with 
CYP1A5 plays an important role in the extreme sensitivity of turkeys to AFB1.  
After the characterization of both CYP1A and 3A homologues from the 
turkey liver, we attempted to determine their relative importance in AFB1 
epoxidation, in turkey liver microsomes. The combined presence of CYP1A5 and 
3A37 in turkey liver, both of which metabolized AFB1 to the toxic exo-AFBO and 
to detoxification products AFM1 and AFQ1, respectively, complicated the kinetic 
analysis of the oxidation of this mycotoxin in turkey liver microsomes.  Although 
both the enzymes are efficient epoxidators of AFB1, the observed kinetics of the 
AFB1 oxidation for CYP1A5 differed from those of CYP3A37. While CYP1A5 
showed hyperbolic Michaelis-Menton, CYP3A37 exhibited sigmoidal Hill‟s 
kinetics, indicative of an allosteric interaction, for the formation of AFB1 
oxidation products.  
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Immunoinhibition studies, utilizing anti-peptide sera directed against 
CYP1A5 and 3A37, revealed that CYP1A5 very likely is the dominant homologue 
in the formation of exo-AFBO at real world in vivo concentrations of AFB1, in the 
turkey liver. Microsomal metabolism studies, in the presence or absence of 
antiserum, using AFB1 concentrations ranging over 0.1-1000 µM, showed that 
CYP1A5 is the major contributor to the formation of exo-AFBO at relatively low 
concentrations of AFB1, reflective of those potentially encountered through 
dietary exposure. CYP3A37, however, efficiently activated higher AFB1 
concentrations, not likely to be achievable in turkey liver in vivo. We also 
concluded that CYP1A5 acts as the higher affinity and CYP3A37 as the lower 
affinity enzyme for AFB1, as indicated by their Km values. In these experiments, 
the kinetics of the formation of different products of AFB1 metabolism, in turkey 
liver microsomes, pretreated with either anti-CYP1A5 or 3A37 immune serum 
was consistent with those observed with the individual P450s expressed in E. 
coli. These studied helped us in not only determining the relative importance of 
CYP1A5 and 3A37, but also to confirm their metabolic specificity, in the 
formation of the metabolites of AFB1.  
Since AFB1 is ubiquitous in corn-based poultry feed, we evaluated the 
chemopreventive potential of probiotic, LGG, on AFB1 toxicity in turkeys. LGG 
binds to AFB1, thus reducing its bioavailability and toxicity. Turkeys fed LGG in 
their diet showed improvements in some key endpoints of aflatoxicosis. Birds 
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which received LGG + AFB1 had significantly higher body and liver weights 
than those of AFB1-alone. Serum profile, histopathological analysis and AFB1-
adduct analysis showed trends toward protective effects of LGG, but the 
differences were not statistically significant. In conclusion, LGG offers some 
protection against aflatoxicosis, thus validating its use as a possible 
chemopreventive; however, chronic studies are required to confirm its use as a 
dietary additive.  
The results of this dissertation have provided insight into the role of P450s 
in the extreme sensitivity of turkeys to AFB1. Commercial turkeys possess P450s 
with high AFB1 epoxidation potential, which is associated with their sensitivity 
to this mycotoxin. Our studies have helped unravel the relative importance of 
CYP1A5 and 3A37, which will contribute toward the development of strategies 
to protect poultry against the deleterious effects of AFB1. Because CYP1A5 is 
likely the predominating isoform bioactivating AFB1 at in vivo dietary 
concentrations, further research investigating the chemopreventives which could 
inhbit CYP1A5, therefore merits study. Another direction may include 
development of CYP1A5 gene knock-out models for poultry and studying their 
susceptibility to AFB1. Based on the results of our studies, inhibition of CYP1A5 
may provide significant improvements in AFB1-associated toxicity in turkeys. In 
fact, the dietary antioxidant BHT was found to have protective effects on AFB1 
toxicity, in part, because of its inhibitory effect on CYP1A5.  
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Several evidences point towards the presence of P450s capable of 
metabolizing xenobiotics in the intestines in other species; although in very small 
quantities as compared to liver.  Therefore, future work may include 
examination of those P450 isoforms in the intestines from turkeys, which may 
play a role in AFB1 epoxidation, before it reaches the liver.  
Our laboratory has established that the extreme sensitivity of turkeys to 
AFB1 is due, in part, to an unfortunate combination of efficient P450 mediated 
epoxidation and deficient detoxification by GSTs. Commercial turkeys lack 
isoforms of GSTs capable of conjugating the exo-AFBO. Future work, which is 
currently on going in our laboratory, includes examination of the GSTs in wild 
turkeys. Although direct comparisons have not been made, wild turkeys appear 
to be relatively resistant to AFB1 as compared to their commercial counterparts. 
The protective traits might have been lost in commercial turkeys, due to the 
intense pressure of selective breeding. By identifying the relevant genetic 
markers for the AF resistance, the protective traits in the commercial varieties, 
may well be restored.  
 Additional work may be done to study other metabolic detoxification 
enzymes, for example, epoxide hydrolase (EH). This enzyme acts on exo-AFBO 
and converts it into a dihydrodiol derivative, which is hydrophilic and thus 
could be excreted from the body. Single nucleotide polymorphisms in the 
microsomal EH have been associated with the risk of development of 
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hepatocellular carcinomas in humans; especially in regions where AFB1 
contaminated foods constitute a staple diet.   
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